

B1

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 August 2001 (16.08.2001)

PCT

(10) International Publication Number
WO 01/58925 A2

(51) International Patent Classification⁷: C07K 1/00

(21) International Application Number: PCT/US01/03917

(22) International Filing Date: 7 February 2001 (07.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/180,911 8 February 2000 (08.02.2000) US
60/239,325 10 October 2000 (10.10.2000) US
60/239,326 10 October 2000 (10.10.2000) US
60/259,448 3 January 2001 (03.01.2001) US

(71) Applicant (for all designated States except US): THE REGENTS OF THE UNIVERSITY OF MICHIGAN [US/US]; 3003 South State Street, Ann Arbor, MI 48109-1280 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LUBMAN, David, M. [US/US]; 2012 Shadford Road, Ann Arbor, MI (US). BARDER, Timothy, J. [US/US]; 8205 South Cass Ave., Suite 111, Darien, IL 60561 (US). WALL, Daniel, B. [US/US]; 1508 Gilbert Ct., #B16, Ann Arbor, MI (US). PARUS, Stephen, J. [US/US]; 2234 Placid Way, Ann Arbor, MI 48105 (US). KACHMAN, Maureen, T. [US/US]; 2230 Parkwood Avenue, Ann Arbor, MI 48104 (US). CHONG, Bathsheba, E. [MY/US]; 822 South Main

#2, Ann Arbor, MI (US). NORTH, Robert [US/US]; 3452 Richards Street, Ann Arbor, MI (US). HORVATH, Thomas [US/US]; 2013 Huron Parkway, Ann Arbor, MI (US). YAN, Fang [CN/US]; 4532 Chemistry Building, Ann Arbor, MI 48105 (US).

(74) Agents: CASIMIR, David, A. et al.; Medlen & Carroll, LLP, 220 Montgomery Street, Suite 2200, San Francisco, CA 94104 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/58925 A2

(54) Title: PROTEIN SEPARATION AND DISPLAY

(57) Abstract: The present invention relates to multi-phase protein separation methods capable of resolving and characterizing large numbers of cellular proteins, including methods for efficiently facilitating the transfer of protein samples between separation phases. In particular, the present invention provides an automated system for the separation, identification, and characterization of protein samples. The present invention thus provides improved methods for the analysis of samples containing large numbers of proteins.

BEST AVAILABLE COPY

PROTEIN SEPARATION AND DISPLAY

This application claims priority benefit of U.S. Provisional Appln. Ser. Nos. 60/180,911, filed 02/08/00, 60/239,325, filed 10/10/00, 60/239,326, filed 10/10/00, and 60/259,448, filed 01/03/01, each of which is herein incorporated by reference in their
5 entireties.

The present invention was made, in part, with government funding under National Institutes of Health under grant No. 2-R01GM49500-5 and the National Science Foundation grant No. DBI-9987220. The government has certain rights in this invention.

10 FIELD OF THE INVENTION

The present invention relates to multi-phase protein separation methods capable of resolving and characterizing large numbers of cellular proteins, including methods for efficiently facilitating the transfer of protein samples between separation phases. In particular, the present invention provides an automated system for the separation,
15 identification, and characterization of protein samples.

BACKGROUND OF THE INVENTION

As the nucleic acid sequences of a number of genomes, including the human genome, become available, there is an increasing need to interpret this wealth of information. While the availability of nucleic acid sequence allows for the prediction
20 and identification of genes, it does not explain the expression patterns of the proteins produced from these genes. The genome does not describe the dynamic processes on the protein level. For example, the identity of genes and the level of gene expression does not represent the amount of active protein in a cell nor does the gene sequence describe post-translational modifications that are essential for the function and activity
25 of proteins. Thus, in parallel with the genome projects there has begun an attempt to understand the proteome (*i.e.*, the quantitative protein expression pattern of a genome under defined conditions) of various cells, tissues, and species. Proteome research

seeks to identify targets for drug discovery and development and provide information for diagnostics (*e.g.*, tumor markers).

An important area of research is the study of the protein content of cells (*i.e.*, the identity of and amount of expressed proteins in a cell). This field requires
5 methods that can separate out large numbers of proteins and can do so quantitatively so that changes in expression or structure of proteins can be detected. The method generally used to achieve such cellular protein separations is 2-D PAGE. This method is capable of resolving hundreds of proteins based upon pI in one dimension and protein size in the second dimension. The proteins separated by this method are
10 visualized using a staining method that can generally be quantified. The result is a 2-dimensional image where the protein map is based on pI and approximate molecular weight. By the use of computer based image analysis techniques, one can search for proteins that are differentially expressed in various cell lines. These methods are used to monitor changes in protein expression that are linked to conditions such as cell
15 transformation and cancer progression, cell aging, the response of cells to environmental insult, and the response of cells to pharmaceutical agents. Once changes in protein expression have been identified, then one can further analyze target proteins to determine their identity and whether they have been altered from their expected structure by sequence changes or post-translational modifications.

20 Although 2-D PAGE is still widely used for protein analysis, the method has several limitations including the fact that it is labor intensive, time consuming, difficult to automate and often not readily reproducible. In addition, quantitation, especially in differential expression experiments, is often difficult and limited in dynamic range. Also, while the 2-D gel does produce an image of the proteins in the cell, the mass
25 determination is often only accurate to 5-10%, and the method is difficult to interface to mass spectrometric techniques for further analysis.

Another limitation of 2-D PAGE is the amount of protein loaded per gel which is generally below 250 μ g. The amount of protein in any given spot may therefore be too low for further analysis. For Coomassie brilliant blue (CBB) stained gels the limit
30 of detection is 100 ng per spot while for silver stained gels the limit of detection is 1 –

10 ng. Furthermore, proteins that have been isolated in 2-D gels are embedded inside the gel structure and are not free in solution, thus making it difficult to extract the protein for further analysis. Because of these limitations, the art is in need of protein mapping methods that are efficient, automated, and have broader resolution capabilities than presently available technologies.

SUMMARY OF THE INVENTION

The present invention relates to multi-phase protein separation methods capable of resolving and characterizing large numbers of cellular proteins, including methods for efficiently facilitating the transfer of protein samples between separation phases. In particular, the present invention provides an automated system for the separation, identification, and characterization of protein samples.

For example, the present invention provides a method for displaying proteins comprising: 1) providing i) a sample comprising a plurality of proteins, ii) a first separating apparatus, and iii) a second separating apparatus; 2) treating the sample with the first separating apparatus to produce a first separated protein sample, wherein the first separated protein sample is collected from the first separating apparatus in a plurality of fractions, each of the fractions defined by a distinct pH range (*i.e.*, each of the fractions containing proteins that are eluted from the first separating apparatus within a particular pH range); treating the first separated protein sample with the second separating apparatus to produce a second separated protein sample; and analyzing the second separated protein sample by mass spectrometry to produce a 2-dimensional protein map. In preferred embodiments, the 2-dimensional protein map comprises a first dimension representing protein pI point. In yet other preferred embodiments, the 2-dimensional protein map further comprises a second dimension representing protein molecular weight.

The present invention also provides a system comprising: a first separating apparatus; a buffer capable of eluting protein from the first separating apparatus in a plurality of fractions; a first delivery apparatus capable of receiving separated protein in the plurality of fractions, each of the fractions defined by a distinct pH range; a

second separating apparatus, wherein the second separating apparatus is configured to receive proteins from the first delivery apparatus; a second delivery apparatus capable of receiving separated protein from the second separating apparatus; a mass spectrometry apparatus configured to receive proteins from the second delivery
5 apparatus; and a processor connected to the system, wherein the processor is capable of producing a 2-dimensional data representation of separated proteins analyzed by the mass spectrometry apparatus. In preferred embodiments, the system further comprises a display system capable of displaying the data representation. In other preferred
10 embodiments, the 2-dimensional data representation comprises a first dimension representing protein pI point, while in yet other preferred embodiments, the 2-dimensional data representation further comprises a second dimension representing protein molecular weight.

The present invention further provides a method for displaying proteins comprising providing: i) a sample comprising a plurality of proteins, ii) an isoelectric
15 separating apparatus, and iii) a reverse phase HPLC separating apparatus; treating the sample with the isoelectric separating apparatus to produce a first separated protein sample; treating said first separated protein sample with said reverse phase HPLC separating apparatus to produce a second separated protein sample; and analyzing the second separated protein sample with mass spectrometry (*e.g.*, ESI or TOF/MS) to
20 produce a 2-dimensional protein map. In preferred embodiments, the isoelectric separating apparatus comprises a liquid phase separating apparatus. In yet further preferred embodiments, the reverse phase HPLC comprises non-porous reverse phase HPLC. In some preferred embodiments, the method further comprises the step of determining the identity of at least one protein in the 2-dimensional protein map. For
25 example, in some embodiments, the identifying comprises comparing at least a portion of said 2-dimensional protein map with a control protein map.

In some preferred embodiments, the sample comprising the plurality of proteins further comprises a buffer, wherein the plurality of proteins are solubilized in the buffer and wherein the buffer is compatible with the two separating apparatuses. In

yet other preferred embodiments, the buffer is further compatible with ESI or TOF/MS.

The present invention also provides a system comprising: an isoelectric separating apparatus; a first delivery apparatus capable of receiving separated protein
5 from the isoelectric separating apparatus; a reverse phase HPLC separating apparatus, wherein the HPLC separating apparatus is configured to receive proteins from the first delivery apparatus; a second delivery apparatus capable of receiving separated protein from the reverse phase HPLC separating apparatus; and an ESI or TOF/MS apparatus configured to receive proteins from the second delivery apparatus. In some
10 embodiments, the system further comprises a processor connected to the system, wherein the processor is capable of producing a data representation of separated proteins analyzed by the ESI or TOF/MS apparatus. In yet other embodiments, the system further comprises a display system capable of displaying the data representation. In preferred embodiments, the display system is capable of displaying
15 the data representation as a 2-dimensional protein map. In particularly preferred embodiments, the 2-dimensional protein map displays a mass spectra in a top view protein band format. In other preferred embodiments, the 2-dimensional protein map has a resolution that allows for the differentiation between phosphorylation states of a protein or other minor variations (e.g., difference in methylation, glycosylation,
20 lipidation, truncation, amino acid substitutions, etc.). In preferred embodiments, the isoelectric separating apparatus comprises a liquid phase separating apparatus. In yet other preferred embodiments, the reverse phase HPLC apparatus comprises a non-porous reverse phase HPLC apparatus.

The present invention further provides a method for displaying proteins
25 comprising providing: a sample comprising a plurality of proteins, a first separating apparatus, wherein the first separating apparatus is capable of (*i.e.*, is configured for) separating proteins based on a first physical property, and a second separating apparatus, wherein the second separating apparatus is a liquid phase separating apparatus and wherein the second separating apparatus is capable of (*i.e.*, is configured
30 for) separating proteins based on a second physical property; treating the sample with

the first separating apparatus to produce a first separated protein sample; treating the first separated protein sample with the second separating apparatus to produce a second separated protein sample; and displaying at least a portion of the second separated protein sample under conditions such that the first and the second physical properties of at least a portion of the plurality of proteins are revealed. In some preferred
5 embodiments, the first and the second physical properties include, but are not limited to, charge, hydrophobicity, and molecular weight. In some embodiments, the displaying results in a two-dimensional display while in other embodiments the display is three-dimensional (*e.g.*, display with a third physical property) or multi-dimensional.

10 In some embodiments, the sample comprising a plurality of proteins further comprises a buffer, wherein said plurality of proteins are solubilized in the buffer and wherein the buffer is compatible with the first and said second separating apparatus. In some preferred embodiments, the buffer is further compatible with mass spectrometry. In some embodiments, the buffer comprises a compound of the formula
15 n-octyl SUGARpyranoside (*e.g.*, n-octyl C₆-C₁₂ glycopyranoside, where C₆-C₁₂ glycopyranoside is a six to twelve carbon sugar pyranoside). The sugar component is not limited to any particular sugar and includes compounds such as n-octyl β-D-glucopyranoside and n-octyl β-D-galactopyranoside.

In some preferred embodiments, the sample comprises a cell lysate (*e.g.*, cells
20 from animals, plants, and microorganisms; cancer cells; tissue culture cell; cells at various stages of development or differentiation; embryonic cells; tissues; etc.). However, the present invention is not limited to the use of cell lysates. For example, the sample may comprise purified and partially purified protein preparations. The present invention is also not limited in the nature of the proteins. For example,
25 proteins may include, but are not limited to, protein fragments, polypeptides, modified proteins (*e.g.*, lipidated, glycosylated, phosphorylated etc.), protein complexes (*e.g.*, protein/protein, protein/nucleic acid), acid proteins, basic proteins, hydrophobic proteins, hydrophilic proteins, membrane proteins, cell surface proteins, nuclear proteins, transcription factors, structural proteins, enzymes, receptors, and the like.

In some embodiments of the present invention the first separating apparatus comprises a liquid phase separating apparatus. However, the first separating apparatus is not limited to liquid phase apparatuses. For example, the first separating apparatus may be gel-based or may be selected from methods including, but not limited to, ion
5 exclusion, ion exchange, normal/reversed phase partition, size exclusion, ligand exchange, liquid/gel phase isoelectric focusing, and adsorption chromatography. In some preferred embodiments, the first separating apparatus comprises an isoelectric focusing apparatus. In some embodiments of the present invention, the second separating apparatus comprises reverse phase HPLC. In some preferred embodiments,
10 the reverse phase HPLC comprises non-porous reverse phase HPLC. Certain embodiments of the present invention may utilize a second separation apparatus that is not liquid phase (*e.g.*, gel-phase).

In some embodiments of the present invention the method further comprises the step of determining the identify of at least one protein of the second separated protein
15 sample. Although the present invention is not limited to any particular method of determining the identify of the protein, in some embodiments, the method comprises analyzing said at least one protein from the second separated protein sample with mass spectrometry.

The present invention also provides a method for characterizing proteins
20 comprising providing: i) a sample comprising a plurality of proteins, ii) a first separating apparatus, wherein the first separating apparatus is capable of (*i.e.*, is configured for) separating proteins based on a first physical property, and iii) a second separating apparatus, wherein the second separating apparatus is a liquid phase separating apparatus and wherein the second separating apparatus is capable of (*i.e.*, is
25 configured for) separating proteins based on a second physical property; treating the sample with the first separating apparatus to produce a first separated protein sample; treating the first separated protein sample with the second separating apparatus to produce a second separated protein sample; and characterizing the second separated protein sample under conditions such that the first and the second physical properties
30 of at least a portion of the plurality of proteins are analyzed. In some embodiments,

the characterizing comprises quantitating the first physical property and the second physical property for two or more proteins in the second protein sample. In other preferred embodiments, the characterizing comprises the step of analyzing at least a portion of the second separated protein sample by mass spectrometry. In yet another embodiment, the characterizing comprises the step of determining the identity of at least one protein from the second separated protein sample with mass spectrometry.

The present invention also provides a method for comparing protein expression patterns comprising providing: i) first and second samples comprising a plurality of proteins, ii) a first separating apparatus, wherein the first separating apparatus is capable of (*i.e.*, is configured for) separating proteins based on a first physical property; and iii) a second separating apparatus, wherein the second separating apparatus is a liquid phase separating apparatus and wherein the second separating apparatus is capable of separating proteins based on a second physical property; treating the first and second samples with the first separating apparatus to produce first and second separated protein samples; treating the first and second separated protein samples with the second separating apparatus to produce third and fourth separated protein samples; and comparing the first and said second physical properties of the third separated protein sample with the first and second physical properties of the fourth separated protein sample. In some embodiments, the first and second samples are combined into a single sample prior to step b) (*i.e.*, the samples are run together rather than in parallel or in sequence). In some embodiments, at least a portion of the proteins in the first sample comprise a first label and at least a portion of the proteins in the second sample comprises a second label. In some embodiments, the comparing comprises the step of analyzing at least a portion of the third and the fourth separated protein samples by mass spectrometry.

The present invention also provides a system comprising: a first separating apparatus, wherein the first separating apparatus is capable of (*i.e.*, is configured for) separating proteins based on a first physical property; a first delivery apparatus capable of (*i.e.*, configured for) receiving separated protein from the first separating apparatus; a second separating apparatus wherein the second separating apparatus is a liquid phase

separating apparatus, wherein the second separating apparatus is capable of (*i.e.*, is configured for) separating proteins based on a second physical property, and wherein the second separating apparatus is capable of (*i.e.*, configured for) receiving proteins from the first delivery apparatus; a detection system capable of (*i.e.*, configured for) detecting proteins produced by the second separating apparatus; a processor connected to the detection system, wherein the processor produces a data representation of the proteins produced by the second separating apparatus; and a display system capable of (*i.e.*, configured for) displaying the data representation under conditions such that the first and second physical properties of at least a portion of the plurality of proteins are revealed. In some embodiments, the system further comprises a second delivery apparatus capable of (*i.e.*, configured for) receiving separated protein from the second separating apparatus; and a mass spectrometry apparatus capable of (*i.e.*, configured for) receiving protein from the second delivery apparatus.

The present invention also provides an method, comprising: providing: i) a sample comprising a plurality of proteins, ii) a first separating apparatus capable of separating proteins based on a first physical property; iii) a second separating apparatus capable of separating proteins based on a second physical property; iv) a mass spectroscopy apparatus capable of separating proteins based on mass; and v) an automated sample handling device; and treating the sample with the first separating apparatus to produce a first separated protein sample collected from the first separating apparatus in a plurality of fractions, each of the fractions defined by a distinct physical property; transferring the first separated protein sample to the second separating apparatus using the automated sample handling device; treating the first separated protein sample with the second separating apparatus to produce a second separated protein sample; transferring the second separated protein sample to the mass spectroscopy apparatus using the automated sample handling device; and analyzing the second separated protein sample with the mass spectroscopy apparatus to produce a 3-dimensional protein map.

In some embodiments, the method further comprises a centralized control network operably linked to the automated sample handling device, the first separating apparatus, the second separating apparatus, and the mass spectroscopy apparatus. In some preferred embodiments, the centralized control network is configured to control
5 the automated sample handling device, the first separating apparatus, the second separating apparatus, and the mass spectroscopy apparatus. In some embodiments, the centralized control network comprises computer memory and a computer processor.

In some embodiments, the method further comprises a solid phase extraction apparatus. In some embodiments, the first separated sample is treated with the solid
10 phase extraction apparatus to treating with the second apparatus. In some embodiments, the automated sample handling device comprises a switchable, multi-channel valve.

In some embodiments, the sample comprising a plurality of proteins further comprises a buffer, wherein the plurality of proteins are solubilized in the buffer and
15 wherein the buffer is compatible with the first separating apparatus, the second separating apparatus, and the mass spectroscopy apparatus. In some preferred embodiments, the buffer comprises a compound of the formula n-octyl SUGARpyranoside. The present invention is not limited to any particular buffer of the formula n-octyl SUGARpyranoside. Indeed, a variety of buffers are contemplated,
20 including but not limited to, n-octyl β -D-glucopyranoside and n-octyl β -D-galactopyranoside. In some embodiments, the sample comprises a cell lysate.

In some embodiments, the first separating apparatus comprises a liquid phase separating apparatus. In some embodiments, the liquid phase separating apparatus in a ion exchange separating apparatus. In some embodiments, the second separating
25 apparatus comprises a reverse phase HPLC separating apparatus. In some embodiments, the reverse phase HPLC comprises non-porous reverse phase HPLC.

In some embodiments, prior to said analyzing the second separated protein sample by mass spectroscopy; the second treated sample is separated into a first portion and a second portion; and the second portion is subjected to enzymatic
30 digestion. In some embodiments, the mass spectrometry step comprises analyzing the

second separated protein sample by ESI or TOF/MS. The present invention is not limited to any particular mass spectroscopy technique. Indeed, a variety of mass spectroscopy techniques are contemplated, including but not limited to, ion trap mass spectrometry, ion trap/time-of-flight mass spectrometry, quadrupole and triple
5 quadrupole mass spectrometry, Fourier Transform (ICR) mass spectrometry, and magnetic sector mass spectrometry.

In some embodiments, the 3-dimensional protein map comprises a first dimension representing protein charge, a second dimension representing protein hydrophobicity, and a third dimension representing protein mass. In some
10 embodiments, a second protein sample comprising a second plurality of proteins is analyzed. In some embodiments, the 3-D protein map comprises a comparison of protein expression patterns between the first protein sample and the second protein sample.

The present invention also provides a centralized control network operably
15 linked to a system, the system comprising: a first separating apparatus; an automated sample handling device; a second separating apparatus operably linked to the first separating apparatus and the sample handling device, wherein the second separating apparatus is configured to receive proteins from the first separating apparatus; a mass spectrometry apparatus operably linked to the second separating apparatus and the
20 sample handling device; wherein the mass spectroscopy apparatus is configured to receive proteins from the second separating apparatus; and wherein the centralized control network is capable of controlling the sample handling device, the first separating apparatus, the second separating apparatus; and the mass spectrometry apparatus.

25 In some embodiments, the centralized control network comprises computer memory and a computer processor. In some preferred embodiments, the centralized control network is capable of producing a 3-dimensional data representation of separated proteins analyzed by the mass spectrometry apparatus. In some embodiments, the automated sample handling device comprises a switchable, multi-channel valve.

In some embodiments, the system further comprises a display system capable of displaying the 3-D data representation. In some embodiments, the 3-dimensional data representation comprises a first dimension representing protein charge, a second dimension representing protein hydrophobicity, and a third dimension representing protein mass.

In some embodiments, the first separating apparatus comprises a liquid phase separating apparatus. In some embodiments, the liquid phase separating apparatus is a ion exchange separating apparatus. In some embodiments, the second separating apparatus comprises a reverse phase HPLC separating apparatus. In some embodiments, the reverse phase HPLC separating apparatus comprises a non-porous reverse phase HPLC apparatus.

DESCRIPTION OF THE FIGURES

Figure 1 shows an example 2-D protein display using Isoelectric Focusing Non-Porous Reverse Phase HPLC (IEF-NP RP HPLC) separation of human erythro leukemia cell lysate proteins in one embodiment of the present invention.

Figure 2 shows a zoom area of a portion of the display in Figure 1 ($pI = 4.2$ to 7.2 and $tR = 6.0$ to 9.0) (right panel showing banding patterns) and a corresponding example of linked HPLC data (left panel showing peaks).

Figure 3 shows a quantification of rotofor fractions in one embodiment of the present invention.

Figure 4 shows NP RP HPLC separation from a Rotofor fraction of HEL cell lysate in one embodiment of the present invention.

Figure 5A and 5B show short (5A) and long (5B) NP RP HPLC separation gradient times for a rotofor fraction of HEL cell lysate in one embodiment of the present invention.

Figure 6 shows an example of Coomassie blue stained 2-D PAGE separation of HEL cell lysate proteins.

Figure 7 shows a direct side-by-side comparison of IEF-NP RP HPLC (four lanes on the left) with 1-D SDS PAGE (four lane on the right) for several Rotofor fractions in certain embodiments of the present invention.

Figures 8A and 8B show MALDI-TOF MS tryptic peptide mass maps for α -enolase isolated by IEF-NP RP HPLC (8A) and by 2-D PAGE (8B).

Figure 9 shows a 2D protein image of Isoelectric Focusing - Non-porous RP HPLC - ESI oa TOF/MS (IEF-NPS RP HPLC-ESI oa TOF/MS) separation of human erythroleukemia cell lysate proteins.

Figure 10 shows a zoom of the 2D protein image from Figure 9 of 35 kDa to 52 kDa mass range.

Figure 11A and 11B show actin multiply charged umbrella with MaxEnt deconvoluted molecular weight mass spectrum. The umbrella for beta and gamma actin is shown in Figure 11A, each form of actin being labeled with the charge state. Figure 11B shows the resulting molecular weight mass spectrum for actin where the two forms of actin are separated.

Figure 12 shows combined protein molecular weight mass spectrum from a Rotofor fraction shown in traditional peak format.

Figure 13 shows a zoom of 2D protein image from Figure 9 of 5 kDa to 40 kDa mass range.

Figure 14 shows a chromatofocusing profile of MCF-10A whole cell lysate.

Figures 15A, B, and C show NP-RP-HPCL-ESI-oaTOF TIC (total ion count) profile of three sample fractions identified in Figure 14.

Figure 16 shows an integrated and deconvoluted TIC profile of the three sample fractions from Figure 15, as generated with MaxEnt1 software.

Figure 17 shows the anion exchange profile of Siberian Permafrost whole cell lysate of sample 23-9-25.

Figures 18A and 18B show the NP-RP-HPLC-ESI-oaTOF TIC profile of two fractions from Figure 17.

GENERAL DESCRIPTION OF THE INVENTION

The present invention relates to multi-phase protein separation methods capable of resolving large numbers of cellular proteins, including methods for efficiently facilitating the transfer of protein samples between separation phases. The methods of the present invention provide protein profile maps for imaging and comparing protein expression patterns. The present invention provides alternatives to traditional 2-D gel separation methods for the screening of protein profiles. Many limitations of traditional 2-D PAGE arise from its use of the gel as the separation media. The present invention provides alternative media for the separation that offer significant advantages over 2-D PAGE techniques. For example, in some embodiments, the present invention provides methods that use two dimensional separations, where the second dimensional separation occurs in the liquid phase, rather than 2-D PAGE techniques where the final separation occurs in gel.

The present invention provides systems and methods for protein separation and mapping that are highly efficient, amenable to automation, and provide detailed resolution. For example, in some methods of the present invention, proteins are separated according to their pI, using isoelectric focusing (IEF) (*e.g.*, in the Rotofor); according to their hydrophobicity using non-porous reverse phase HPLC (NPS RP HPLC); and according to mass using ESI or TOF/MS or other mass spectrometry techniques. The present invention further provides novel techniques for eluting proteins from a separation apparatus (*e.g.*, the first phase separation apparatus). For example, in one embodiment of the present invention, the proteins eluted from the first dimension are "peeled off" from the column according to their pH, either one pH unit or fraction thereof, at a time. In some embodiments, these focused liquid fractions are then separated according to their hydrophobicity and size (or other desired properties) in the second dimension. Liquid fractions from, for example, NP-RP-HPLC can be conveniently analyzed directly on-line using mass spectrometry (*e.g.*, ESI-*oa*TOF) to obtain their molecular weight and relative abundance, which provides a third dimension. As a result, a virtual 2-D protein image is created and is analogous to a 2-D gel image.

Experiments conducted during the development of the present invention have demonstrated that these methods are capable of separating large numbers of proteins. The 2-D image of these proteins, analogous to that of a 2-D gel, can be generated for the purpose of observing distinctive patterns from a particular cell line. This protein
5 pattern provides relative quantitative information, high mass resolution and high accuracy pI and mass values. Given that the intensity, mass and pI values are reproducible, one can study differential expression of proteins where the resulting 2-D images from different cells, tissues, or samples can be quantitatively compared to identify points of interest. Furthermore, automation and speed of analysis are greatly
10 facilitated given that the proteins remain in the liquid phase throughout the separation. The method, abbreviated IEF-NPS RP HPLC-ESI or TOF/MS is shown to be a viable alternative for the separation of complex protein mixtures and the generation of high-resolution 2-D images of cellular protein expression.

In some embodiments of the present invention, proteins are separated in a first
15 dimension using any of a large number of protein separation techniques including, but not limited to, ion exclusion, ion exchange, normal/reversed phase partition, size exclusion, ligand exchange, liquid/gel phase isoelectric focusing, and adsorption chromatography. In some preferred embodiments of the present invention, the first dimension is a liquid phase separation method. The sample from the first separation is
20 passed through a second dimension separation. In preferred embodiments of the present invention, the second dimension separation is conducted in liquid phase. The products from the second dimension separation are then characterized. For example, in preferred embodiments, the products of the second separation step are detected and displayed in a 2-D format based on the physical properties of the proteins that were
25 distinguished in the first and second separation steps (*e.g.*, under conditions such that the first and the second physical properties are revealed for at least a portion of the proteins). The products may be further analyzed, for example, by mass spectrometry to determine the mass and/or identity of the products or a subset of the products. In these embodiments, a three dimensional characterization can be applied (*i.e.*, based on
30 the physical properties of the first two separation steps and the mass spectrometry

data). It is contemplated that other protein processing steps can be conducted at any stage of the process.

In certain embodiments of the present invention, the steps are combined in an automated system. In preferred embodiments, each of the steps is automated. For example, the present invention provides a system that includes each of the separation and detection elements in operable combination so that a protein sample is applied to the system and the user receives expression map displays or other desired data output. To achieve automation, in preferred embodiments, the products of each step should be compatible with the subsequent step or steps.

In one illustrative embodiment of the present invention proteins are separated according to their pI, using isoelectric focusing (IEF) in a Rotofor and according to their hydrophobicity and molecular weight using NP RP HPLC. This combined separation method is abbreviated IEF-NP RP HPLC. When coupled with mass spectrometry (MS) this technique becomes three-dimensional and allows for the creation of a protein map that tells the pI and the molecular weight of the proteins in question. This information can be plotted in an image that also depicts protein abundance. The end result is a high-resolution image showing a complex pattern of proteins separated by pI and molecular weight and indicating relative protein abundances. This image can be used to determine how the proteins in a given cell line or tissue may change due to some disease state, pharmaceutical treatment, natural or induced differentiation, or change in environmental conditions. The image allows the observer to determine changes in pI, molecular weight, and abundance of any protein in the image. When interfaced to MS the identity of any target protein may also be obtained via enzymatic digests and peptide mass map analyses. In addition, this technique has the advantage of very high loadability (*e.g.*, 1 gram) such that the lower abundance proteins may be detected.

In traditional 2-D PAGE separation and display techniques, the second phase separation is conducted in a gel (*i.e.*, not a liquid phase) and the proteins are separated and detected by differences in molecular weight. In contrast, in some embodiments of the present invention, the second phase separation is conducted in liquid phase. The

products of the second phase separation techniques of the present invention are much more amenable to further characterization and to interpretation of data produced from the second phase. For example, in some embodiments of the present invention, the second phase is conducted using HPLC where the separated protein products are readily detected as peak fractions and interpreted and displayed in two dimensions by a computer based on the physical properties of the first and second separation steps. The products of HPLC separation, being in the liquid phase, are readily used in further detection steps (*e.g.*, mass spectrometry). The methods of the present invention, as compared to traditional 2-D PAGE, allow more sample to be analyzed, are more efficient, facilitate automation, and allow for the analysis of proteins that are not detectable with 2-D PAGE.

For example, in one illustrative embodiment of the present invention, the protein profile of human erythroleukemia (HEL) cells has been analyzed using the methods of the present invention as well as traditional gel based methods for comparison purposes. Two-dimensional images were generated representing each of the separation methods used. Proteins were separated and then collected using both the IEF-NP RP HPLC of the present invention and 2-D PAGE methods. These proteins were then enzymatically digested and the peptide mass maps were determined by MALDI-TOF MS (if a protein cannot be unambiguously identified by this method, further analysis is made by any number of techniques including, but not limited to, LC/MS-MS, PSD-MALDI, NMR, Western blotting, Edman sequence analysis and mass spectrometry can help with further analysis of proteins [See *e.g.*, Yates, J. Mass Spec., 33:1 (1998); Chen *et al.*, Rap. Comm. Mass Spec., 13:1907 (1999); Neubauer and Mann, Anal. Chem. 71:235 (1999); Zugaro *et al.*, Electrophoresis 19:867 (1998); Immler *et al.*, Electrophoresis 19:1015 (1998); Reid *et al.*, Electrophoresis 19:946 (1998); Rosenfeld, *et al.*, Anal. Biochem., 203:173 (1992); Matsui *et al.*, Electrophoresis 18:409 (1997); Patterson and Aebersold, Electrophoresis 16:1791 (1995)]).

In some embodiments, the proteins were tentatively identified using MS-Fit to search the peptide mass maps against the Swiss and NCBI protein databases. This work demonstrated that a large number of proteins, with a useful mass range, were separated using the methods of the present invention and that a 2-D image of these proteins was reproducibly generated for the purpose of observing distinctive patterns that are associated with a particular cell line. The methods of the present invention allowed for the detection of proteins not observed with the 2-D PAGE technique. Automation and speed of analysis are also greatly facilitated given that the proteins remain in the liquid phase throughout the separation.

In some embodiments, the present invention provides an automated protein separation and characterization system. The system is fully integrated and transfers and coordinates multi-phase, orthogonal separation methods. In some embodiments, the information is transferred by the automated system to software for the generation of multi-dimensional protein maps. Automation provides increased speed, efficiency, and sample recovery while eliminating potential sources of contamination and sample loss.

Thus, the methods of the present invention are shown to be an advantageous technique for the generation of images of protein expression profiles as well as for the collection of individual proteins for further analyses. These capabilities allow one to monitor changes in protein expression that are linked to differentiation pathways as well as particular conditions such as cancer (*See e.g.*, Hanash, *Advances in Electrophoresis*; Chrambach, A., Editor, pp 1-44 [1998]), cell aging (*See e.g.*, Steller, *Science* 267:1445 [1995]), the response of cells to environmental insult (*See e.g.*, Welsh *et al.*, *Biol. Reprod.*, 55:141 [1996]), or the response of cells to some pharmaceutical agent. Having identified significant changes in protein expression, one can then further analyze proteins of interest to determine their identity and whether they have been altered from their expected structure by sequence changes or post-translational modifications.

Definitions

To facilitate an understanding of the present invention, a number of terms and phrases are defined below:

As used herein, the term "multiphase protein separation" refers to protein
5 separation comprising at least two separation steps. In some embodiments, multiphase protein separation refers to two or more separation steps that separate proteins based on different physical properties of the protein (*e.g.*, a first step that separates based on protein charge and a second step that separates based on protein hydrophobicity).

As used herein, the term "protein profile maps" refers to representations of the
10 protein content of a sample. For example, "protein profile map" includes 2-dimensional displays of total protein expressed in a given cell. In some embodiments, protein profile maps may also display subsets of total protein in a cell. Protein profile maps may be used for comparing "protein expression patterns" (*e.g.*, the amount and identity of proteins expressed in a sample) between two or more samples. Such
15 comparing find use, for example, in identifying proteins that are present in one sample (*e.g.*, a cancer cell) and not in another (*e.g.*, normal tissue), or are over- or under-expressed in one sample compared to the other.

As used herein, the term "separating apparatus capable of separating proteins based on a physical property" refers to compositions or systems capable of separating
20 proteins (*e.g.*, at least one protein) from one another based on differences in a physical property between proteins present in a sample containing two or more protein species. For example, a variety of protein separation columns and composition are contemplated including, but not limited to ion exclusion, ion exchange, normal/reversed phase partition, size exclusion, ligand exchange, liquid/gel phase
25 isoelectric focusing, and adsorption chromatography. These and other apparatuses are capable of separating proteins from one another based on their size, charge, hydrophobicity, and ligand binding affinity, among other properties. A "liquid phase" separating apparatus is a separating apparatus that utilizes protein samples contained in liquid solution, wherein proteins remain solubilized in liquid phase during separation

and wherein the product (*e.g.*, fractions) collected from the apparatus are in the liquid phase. This is in contrast to gel electrophoresis apparatuses, wherein the proteins enter into a gel phase during separation. Liquid phase proteins are much more amenable to recovery/extraction of proteins as compared to gel phase. In some embodiments,
5 liquid phase proteins samples may be used in multi-step (*e.g.*, multiple separation and characterization steps) processes without the need to alter the sample prior to treatment in each subsequent step (*e.g.*, without the need for recovery/extraction and resolubilization of proteins).

As used herein, the term "displaying proteins" refers to a variety of techniques
10 used to interpret the presence of proteins within a protein sample. Displaying includes, but is not limited to, visualizing proteins on a computer display representation, diagram, autoradiographic film, list, table, chart, etc. "Displaying proteins under conditions that first and second physical properties are revealed" refers to displaying proteins (*e.g.*, proteins, or a subset of proteins obtained from a separating apparatus)
15 such that at least two different physical properties of each displayed protein are revealed or detectable. For example, such displays include, but are not limited to, tables including columns describing (*e.g.*, quantitating) the first and second physical property of each protein and two-dimensional displays where each protein is represented by an X,Y locations where the X and Y coordinates are defined by the
20 first and second physical properties, respectively, or vice versa. Such displays also include multi-dimensional displays (*e.g.*, three dimensional displays) that include additional physical properties.

As used herein, "characterizing protein samples under conditions such that first and second physical properties are analyzed" refers to the characterization of two or
25 more proteins, wherein two different physical properties are assigned to each analyzed (*e.g.*, displayed, computed, etc.) protein and wherein a result of the characterization is the categorization (*i.e.*, grouping and/or distinguishing) of the proteins based on these two different physical properties. For example, in some embodiments, two proteins are separated based on isoelectric point and hydrophobicity.

As used herein, the term "comparing first and second physical properties of separated protein samples" refers to the comparison of two or more protein samples (or individual proteins) based on two different physical properties of the proteins within each protein sample. Such comparing includes grouping of proteins in the samples
5 based on the two physical properties and comparing certain groups based on just one of the two physical properties (*i.e.*, the grouping incorporates a comparison of the other physical property).

As used herein, the term "delivery apparatus capable of receiving a separated protein from a separating apparatus" refers to any apparatus (*e.g.*, microtube, trough,
10 chamber, etc.) that receives one or more fractions or protein samples from a protein separating apparatus and delivers them to another apparatus (*e.g.*, another protein separation apparatus, a reaction chamber, a mass spectrometry apparatus, etc.).

As used herein, the term "detection system capable of detecting proteins" refers to any detection apparatus, assay, or system that detects proteins derived from a
15 protein separating apparatus (*e.g.*, proteins in one or fractions collected from a separating apparatus). Such detection systems may detect properties of the protein itself (*e.g.*, UV spectroscopy) or may detect labels (*e.g.*, fluorescent labels) or other detectable signals associated with the protein. The detection system converts the detected criteria (*e.g.*, absorbance, fluorescence, luminescence etc.) of the protein into
20 a signal that can be processed or stored electronically or through similar means (*e.g.*, detected through the use of a photomultiplier tube or similar system).

As used herein, the term "buffer compatible with an apparatus" and "buffer compatible with mass spectrometry" refer to buffers that are suitable for use in such apparatuses (*e.g.*, protein separation apparatuses) and techniques. A buffer is suitable
25 where the reaction that occurs in the presence of the buffer produces a result consistent with the intended purpose of the apparatus or method. For example, a buffer compatible with a protein separation apparatus solubilizes the protein and allows proteins to be separated and collected from the apparatus. A buffer compatible with mass spectrometry is a buffer that solubilizes the protein or protein fragment and

allows for the detection of ions following mass spectrometry. A suitable buffer does not substantially interfere with the apparatus or method so as to prevent its intended purpose and result (*i.e.*, some interference may be allowed).

As used herein, the term "automated sample handling device" refers to any
5 device capable of transporting a sample (*e.g.*, a separated or un-separated protein sample) between components (*e.g.*, separating apparatus) of an automated method or system (*e.g.*, an automated protein characterization system). An automated sample handling device may comprise physical means for transporting sample (*e.g.*, multiple lines of tubing connected to a multi-channel valve). In some embodiments, an
10 automated sample handling device is connected to a centralized control network.

As used herein, the term "switchable multi channel valve" refers to a valve that directs the flow of liquid through an automated sample handling device. The valve preferably has a plurality of channels (*e.g.*, 2 or more, and preferably 4 or more, and more preferably, 6 or more). In addition, in some embodiments, flow to individual
15 channels is "switched" on an off. In some embodiments, valve switching is controlled by a centralized control system. A switchable multi-channel valve allows multiple apparatus to be connected to one automated sample handler. For example, sample can first be directed through one apparatus of a system (*e.g.*, a first chromatography apparatus). The sample can then be directed through a different channel of the valve
20 to a second apparatus (*e.g.*, a second chromatography apparatus).

As used herein, the terms "centralized control system" or "centralized control network" refer to information and equipment management systems (*e.g.*, a computer processor and computer memory) operable linked to multiple devices or apparatus (*e.g.*, automated sample handling devices and separating apparatus). In preferred
25 embodiments, the centralized control network is configured to control the operations or the apparatus an device linked to the network. For example, in some embodiments, the centralized control network controls the operation of multiple chromatography apparatus, the transfer of sample between the apparatus, and the analysis and presentation of data.

As used herein, the terms "computer memory" and "computer memory device" refer to any storage media readable by a computer processor. Examples of computer memory include, but are not limited to, RAM, ROM, computer chips, digital video disc (DVDs), compact discs (CDs), hard disk drives (HDD), and magnetic tape.

5 As used herein, the term "computer readable medium" refers to any device or system for storing and providing information (*e.g.*, data and instructions) to a computer processor. Examples of computer readable media include, but are not limited to, DVDs, CDs, hard disk drives, magnetic tape and servers for streaming media over networks.

10 As used herein, the terms "processor" and "central processing unit" or "CPU" are used interchangeably and refers to a device that is able to read a program from a computer memory (*e.g.*, ROM or other computer memory) and perform a set of steps according to the program.

15 As used herein, the term "directly feeding" a protein sample from one apparatus to another apparatus refers to the passage of proteins from the first apparatus to the second apparatus without any intervening processing steps. For example, a protein that is directly fed from a protein separating apparatus to a mass spectrometry apparatus does not undergo any intervening digestion steps (*i.e.*, the protein received by the mass spectrometry apparatus is undigested protein).

20 As used herein, the term "sample" is used in its broadest sense. In one sense it can refer to a cell lysate. In another sense, it is meant to include a specimen or culture obtained from any source, including biological and environmental samples. Biological samples may be obtained from animals (including humans) and encompass fluids, solids, tissues, and gases. Biological samples include blood products (*e.g.*, plasma and serum), saliva, urine, and the like and includes substances from plants and
25 microorganisms. Environmental samples include environmental material such as surface matter, soil, water, and industrial samples. These examples are not to be construed as limiting the sample types applicable to the present invention.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a novel multi-dimensional separation method that is capable of resolving large numbers of cellular proteins. The following discussion is provided in four sections: I) two-phase separation techniques; II) improved elution techniques; III) mass spectroscopic analysis and 2-D display systems and methods; and IV) automated 3D HPLC/MC methods for rapid protein characterization.

I) Two-Phase Separation Techniques

The first dimension separates proteins based on a first physical property. For example, in some embodiments of the present invention proteins are separated by pI using isoelectric focusing in the first dimension (*See e.g.*, Righetti, Laboratory Techniques in Biochemistry and Molecular Biology; Work, T. S.; Burdon, R. H., Elsevier: Amsterdam, p 10 [1983]). However, the first dimension may employ any number of separation techniques including, but not limited to, ion exclusion, ion exchange, normal/reversed phase partition, size exclusion, ligand exchange, liquid/gel phase isoelectric focusing, and adsorption chromatography. In some embodiments (*e.g.*, some automated embodiments), it is preferred that the first dimension be conducted in the liquid phase to enable products of the separation step to be fed directly into a second liquid phase separation step.

The second dimension separates proteins based on a second physical property (*i.e.*, a different property than the first physical property) and is preferably conducted in the liquid phase (*e.g.*, liquid-phase size exclusion). For example, in some embodiments of the present invention proteins are separated by hydrophobicity using non-porous reversed phase HPLC in the second dimension (*See e.g.*, Liang *et al.*, Rap. Comm. Mass Spec., 10:1219 [1996]; Griffin *et al.*, Rap. Comm. Mass Spec., 9:1546 [1995]; Opitck *et al.*, Anal. Biochem. 258:344 [1998]; Nilsson *et al.*, Rap. Comm. Mass Spec., 11:610 [1997]; Chen *et al.*, Rap. Comm. Mass Spec., 12:1994 [1998]; Wall *et al.*, Anal. Chem., 71:3894 [1999]; Chong *et al.*, Rap. Comm. Mass Spec.,

13:1808 [1999]). This method provides for exceptionally fast and reproducible high-resolution separations of proteins according to their hydrophobicity and molecular weight. The non-porous (NP) silica packing material used in these reverse phase (RP) separations eliminates problems associated with porosity and low recovery of larger proteins, as well as reducing analysis times by as much as one third. Separation efficiency remains high due to the small diameter of the spherical particles, as does the loadability of the NP RP HPLC columns. However, the second dimension may employ any number of separation techniques. For example, in one embodiment, 1-D SDS PAGE lane gel is used. Having the second dimension conducted in the liquid phase facilitates efficient analysis of the separated proteins and enables products to be fed directly into additional analysis steps (e.g., directly into mass spectrometry analysis).

In certain embodiments of the present invention, proteins obtained from the second separation step are mapped using software (available from Dr. Stephen J. Parus, University of Michigan, Department of Chemistry, 930 N. University Ave., Ann Arbor, MI 48109-1055) in order to create a protein pattern analogous to that of the 2-D PAGE image--although based on the two physical properties used in the two separation steps rather than by a second gel-based size separation technique. In some embodiments, RP HPLC peaks are represented by bands of different intensity in the 2-D image, according to the intensity of the peaks eluting from the HPLC. In some embodiments, peaks are collected as the eluent of the HPLC separation in the liquid phase.

In some embodiments, the proteins collected from the second dimension were identified using proteolytic enzymes, MALDI-TOF MS and MSFit database searching. In an example using human erythroleukemia cell lysate, using IEF-NP RP HPLC, approximately 700 bands were resolved in a pI range from 3.2 to 9.5 and 38 different proteins with molecular weights ranging from 12 kDa to 75 kDa were identified. In comparison to a 2-D gel separation of the same human erythroleukemia (HEL) cell line lysate, the IEF-NP RP HPLC produced improved resolution of low mass and basic proteins. In addition, the proteins remained in the liquid phase throughout the

separation, thus making the entire procedure highly amenable to automation and high throughput.

Certain preferred embodiments are described in detail below. These illustrative examples are not intended to limit the scope of the invention. For example, although
5 the examples are described using human tissues and samples, the methods and apparatuses of the present invention can be used with any desired protein samples including samples from plants and microorganisms.

A. IEF-NP RP HPLC Method

The following description provides certain preferred embodiments for
10 conducting isoelectric separation (first dimension) and NP RP HPLC separation (second dimension) according to the methods of the present invention.

1. IEF Separation

Proteins are extracted from cells using a lysis buffer. To facilitate an efficient process, this lysis buffer should be compatible with the downstream separation and
15 analysis steps (*e.g.*, NP RP HPLC and MALDI-TOF-MS) to allow direct use of the products from each step into subsequent steps. Such a buffer is an important aspect of automating the process. Thus, the preferred buffer should meet two criteria: 1) it solubilizes proteins and 2) it is compatible with each of the steps in the separation/analysis methods. Although the present invention provides suitable buffers
20 for use in the particular method configurations described below, one skilled in the art can determine the suitability of a buffer for any particular configuration by solubilizing protein sample in the buffer. If the buffer solubilizes the protein, the sample is run through the particular configuration of separation and detection methods desired. A positive result is achieved if the final step of the desired configuration produces
25 detectable information (*e.g.*, ions are detected in a mass spectrometry analysis). Alternately, the product of each step in the method can be analyzed to determine the presence of the desired product (*e.g.*, determining whether protein elutes from the separation steps).

After extraction in the lysis buffer, proteins are initially separated in a first dimension. The goal in this step is that the proteins are isolated in a liquid fraction that is compatible with subsequent NP RP HPLC and mass spectrometry steps. In these embodiments, n-octyl β -D-glucopyranoside (OGl, from Sigma) is used in the buffer. n-octyl β -D-glucopyranoside is one of the few detergents that is compatible with both NP RP HPLC and subsequent mass spectrometry analyses. It is contemplated that detergents of the formula n-octyl SUGARpyranoside find use in these embodiments. The lysis buffer utilized was 6M urea, 2M thiourea, 1.0 % n-octyl β -D-glucopyranoside, 10 mM dithioerythritol and 2.5 % (w/v) carrier ampholytes (3.5 to 10 pI)). After extraction, the supernatant protein solution is loaded to a device that can separate the proteins according to their pI by isoelectric focusing (IEF). Here the proteins are solubilized in a running buffer that again should be compatible with NP RP HPLC. A suitable running buffer is 6M urea, 2M thiourea, 0.5 % n-octyl β -D-glucopyranoside, 10 mM dithioerythritol and 2.5 % (w/v) carrier ampholytes (3.5 to 10 pI).

Three exemplary devices that may be used for this step are:

a) Rotofor

This device (Biorad) separates proteins in the liquid phase according to their pI (See e.g., Ayala *et al.*, Appl. Biochem. Biotech. 69:11 [1998]). This device allows for high protein loading and rapid separations that require only four to six hours to perform. Proteins are harvested into liquid fractions after a 5-hour IEF separation. These liquid fractions are ready for analysis by NP RP HPLC. This device can be loaded with up to 1 g of protein.

b) Carrier Ampholyte based slab gel IEF separation with a whole gel eluter

In this case the protein solution is loaded onto a slab gel and the proteins separate in to a series of gel-wide bands containing proteins of the same pI. These proteins are then harvested using a whole gel eluter (WGE, from Biorad). Proteins are

then isolated in liquid fractions that are ready for analysis by NP RP HPLC. This type of gel can be loaded with up to 20 mg of protein.

c) IPG slab gel IEF separation with a whole gel eluter

Here the proteins are loaded onto a immobiline pI gradient slab gel and separated into a series of gel-wide bands containing proteins of the same pI. These proteins are electro-eluted using the WGE into liquid fractions that are ready for analysis by NP RP HPLC. The IPG gel can be loaded with at least 60 mg of protein.

2. Protein Separation by NP RP HPLC

Having obtained liquid fractions containing large amounts of pI-focused proteins, the second dimension separation is non-porous RP HPLC. The present invention provides the novel combination of employing non-porous RP packing materials (Eichrom) with another RP HPLC compatible detergent (e.g., n-octyl β -D-galactopyranoside) to facilitate the multi-phase separation of the present invention. This detergent is also compatible with mass spectrometry due to its low molecular weight. The use of these types of RP HPLC columns for protein separations as a second dimension separation after IEF in order to obtain a 2-D protein separation is a novel feature of the present invention. These columns are well suited to this task as the non-porous packing they contain provides optimal protein recovery and rapid efficient separations. It should be noted that though several detergents have been mentioned thus far for increasing protein solubility while being compatible with RP HPLC there are many other different low molecular weight non-ionic detergents that could be used for this purpose. Several important features that allow the RP HPLC to work as a second dimension are as follows: The mobile phase should contain a low level of a non-ionic low molecular weight detergent such as n-octyl β -D-glucopyranoside or n-octyl β -D-galactopyranoside as these detergents are compatible with RP HPLC and also with later mass spectrometry analyses (unlike many other detergents); the column should be held at a high temperature (around 60 °C); and the

column should be packed with non-porous silica beads to eliminate problems of protein recovery associated with porous packings.

3. Protein Detection and Identification via Mass Spectrometry

In some embodiments of the present invention, the products of the second separation step are further characterized using mass spectrometry. For example, the proteins that elute from the NP RP HPLC separation are analyzed by mass spectrometry to determine their molecular weight and identity. For this purpose the proteins eluting from the separation can be analyzed simultaneously to determine molecular weight and identity. A fraction of the effluent is used to determine molecular weight by either MALDI-TOF-MS or ESI oa TOF (LCT, Micromass) (*See e.g.*, U.S. Pat. No. 6,002,127). The remainder of the eluent is used to determine the identity of the proteins via digestion of the proteins and analysis of the peptide mass map fingerprints by either MALDI-TOF-MS or ESI oa TOF. The molecular weight 2-D protein map is matched to the appropriate digest fingerprint by correlating the molecular weight total ion chromatograms (TIC's) with the UV-chromatograms and by calculation of the various delay times involved. The UV-chromatograms are automatically labeled with the digest fingerprint fraction number. The resulting molecular weight and digest mass fingerprint data can then be used to search for the protein identity via web-based programs like MSFit (UCSF).

4. Automation

All of the above described steps are automated, for example, into one discrete instrument. In one illustrative embodiment, the first dimension is carried out by a Rotofor, with the harvested liquid fractions being directly applied to the second dimension non-porous RP HPLC apparatus through the appropriate tubing. The products from the second dimension separation are then scanned and the data interpreted and displayed as a 2-D representation using the appropriate computer hardware and software. Alternately, the products from the second dimension fractions are sent through the appropriate microtubing to a mass spectrometry pre-reaction

chamber where the samples are treated with the appropriate enzymes to prepare them for mass spectrometry analysis. The samples are then analyzed by mass spectrometry and the resulting data is received and interpreted by a processor. The output data represents any number of desired analyses including, but not limited to, identity of the proteins, mass of the proteins, mass of peptides from protein digests, dimensional displays of the proteins based on any of the detected physical criteria (*e.g.*, size, charge, hydrophobicity, etc.), and the like. In preferred embodiments, the proteins samples are solubilized in a buffer that is compatible with each of the separation and analysis units of the apparatus. Using the automated systems of the present invention provides a protein analysis system that is an order of magnitude less expensive than analogous automation technology for use with 2-D gels (*See e.g.*, Figeys and Aebersold, *J. Biomech. Eng.* 121:7 [1999]; Yates, *J. Mass Spectrom.*, 33:1 [1998]; and Pinto *et al.*, *Electrophoresis* 21:181 [2000]).

5. Software and Data Presentation

The data generated by the above listed techniques may be presented as 2-D images much like the traditional 2-D gel image. In some embodiments, the chromatograms, TIC's or integrated and deconvoluted mass spectra are converted to ASCII format and then plotted vertically, using a 256 step gray scale, such that peaks are represented as darkened bands against a white background. The scale could also be in a color format. The image generated by this method provides information regarding the pI, hydrophobicity, molecular weight and relative abundance of the proteins separated. Thus the image represents a protein pattern that can be used to locate interesting changes in cellular protein profiles in terms of pI, hydrophobicity, molecular weight and relative abundance. Naturally the image can be adjusted to show a more detailed zoom of a particular region or the more abundant protein signals can be allowed to saturate thereby showing a clearer image of the less abundant proteins. This information can be used to assess the impact of disease state, pharmaceutical treatment, and environmental conditions. As the image is automatically digitized it may be readily stored and used to analyze the protein profile of the cells in question.

Protein bands on the image can be hyper-linked to other experimental results, obtained via analysis of that band, such as peptide mass fingerprints and MSFit search results. Thus all information obtained about a given 2-D image, including detailed mass spectra, data analyses, and complementary experiments (*e.g.*, immuno-affinity and peptide sequencing) can be accessed from the original image.

The data generated by the above-listed techniques may also be presented as a simple read-out. For example, when two or more samples are compared (*See*, Section J, below), the data presented may detail the difference or similarities between the samples (*e.g.*, listing only the proteins that differ in identity or abundance between the samples). In this regard, when the differences between samples (*e.g.*, a control sample and an experimental sample) are indicative of a given condition (*e.g.*, cancer cell, toxin exposure, etc.), the read-out may simply indicate the presence or identity of the condition. In one embodiment, the read-out is a simple +/- indication of the presence of particular proteins or expression patterns associated with a specific condition that is to be analyzed.

6. IEF-NP RP HPLC in Operation

The IEF-NP RP HPLC image shown in Figure 1 is a digital representation of a 2-dimensional separation of a whole cell protein lysate from a human erythroleukemia (HEL) cell line. This image is designed to offer the same advantages of pattern recognition and protein profiling that may be obtained using a 2-D gel. The horizontal and vertical dimensions are in terms of isoelectric point and protein hydrophobicity, respectively. The isoelectric focusing step, performed using the Rotofor, resulted in 20 protein fractions ranging in pH from 3.2 to 9.5. These fractions were then injected onto a non-porous reversed phase column for separation by HPLC and detection by UV absorbance (214 nm). The resulting chromatograms were converted to ASCII format and then plotted vertically, using a 256 step gray scale, such that peaks are represented as darkened bands against a white background. Protein profiles may be viewed in greater detail by using the zoom feature as shown in Figure 2 and/or by

selecting a particular Rotofor fraction and observing the NP RP HPLC chromatogram as shown in the left panel of Figure 2. The zoom and chromatogram image features provide a means to observe details in band patterns that may not be observable in the original image (*See*, Figure 1). In addition, because of the limitations of the 256 step gray scale representation the band intensities in areas 1, 2 and 3 of Figure 1 were rescaled by a factor of 3 to better show the low abundance proteins. This was preferred since the presence of several high abundance protein bands may cause low intensity bands in some regions to be undetected. In Figure 1, the total peak area for each individual chromatogram was scaled to reflect the relative amount of protein that was found in the original Rotofor fraction (*See*, Figure 3). The band intensities in different chromatograms can therefore be compared directly thus providing a true image of relative protein abundance in the cell lysate. The width of the Rotofor fraction columns was adjusted to represent their estimated pH range. The molecular weight of proteins observed by IEF-NP RP HPLC ranged from 12 kDa to 75 kDa. Typical NP RP HPLC separations, as shown in Figure 4, resulted in 35 peaks in 10.5 minutes. The total number of peaks that could be observed from all 20 fractions is estimated to be approximately 700.

The gradient time (t_G) used in the above experiments is very short and a significant increase in peak capacity is expected with longer gradients. This is shown using Rotofor fraction 17 where two separations were performed with gradient times of 10.5 minutes (*See*, Figure 5A) and 21 minutes (*See*, Figure 5B). With $t_G = 10.5$ minutes, the average peak width was 0.14 minutes and the peak capacity was therefore 75. The actual number of peaks resolved was 35. With $t_G = 21$ minutes the average peak width was 0.23 minutes and the peak capacity was therefore 91. The actual number of peaks resolved was 51. Using the longer separation time with $t_G = 21$ minutes the total number of peaks observed should increase from 700 to 1000. However, it should be noted that when using mass spectrometric detection, that sufficient resolution should be available to ultimately resolve the same number of peaks without using a longer gradient time.

The proteins in a representative sampling of these peaks were identified using the traditional approach of enzymatic digestion, MALDI-TOF MS peptide mass analysis and MSFit database searching. The magnification of the IEF-NP RP HPLC image enables the viewer to perceive more bands than is possible to observe from the whole image. In addition, as shown in Figure 2, the viewer may select a particular band format chromatogram and observe the traditional peak format of the chromatogram in a window to the left of the image. This allows the observer to use the peak format chromatogram to find partially resolved peaks that may not be observable in the band format chromatogram. Five standard protein bands are shown in the left-most column where the masses range from 14.2 kDa up to 67 kDa. As RP HPLC separates proteins by hydrophobicity, these standards are not molecular weight markers as in a traditional 1-D gel. Rather, they are used to indicate the range of protein molecular weights that may be observed. Ten different proteins are labeled on the image although many more proteins were identified as shown in Table 1, below. In some embodiments of the present invention, where it is desired that certain proteins or classes of proteins are to be detected, the starting protein sample may be selectively labeled. After the proteins are passed through the separation step, detection of the proteins can be limited to those that contain the selective label.

B. Protein Separation by 2-D SDS PAGE

The image in Figure 1 represents the IEF-NP RP HPLC separation of the HEL cell protein lysate and the image in Figure 6 represents the Coomassie blue (CBB) stained 2-D SDS PAGE separation of the same HEL cell line lysate. The pI range for this gel is the same as that used for the Rotofor separation and the molecular weight range is from 8 kDa to 140 kDa. As with the IEF-NP RP HPLC separation a representative sampling of the isolated proteins was identified using enzymatic digestion, MALDI-TOF MS and MSFit methods (*See e.g.*, Rosenfeld *et al.*, Anal. Biochem. 203:173 [1992]). For the target protein mass range of this study (10 kDa – 70 kDa) approximately 188 protein spots are observed on the CBB stained gel, 355 from the CBB stained polyvinylidene difluoride (PVDF) blot, and 652 from the silver

stained gel as estimated using BioImage 2D Analyzer Version 6.1 software (Genomic Solutions). The total spot capacity for the 2-D gel separation is estimated to be 2100. The proteins identified from the gel are labeled on the image and also shown in Table 2, below. An image of another 2-D gel separation of HEL cell proteins can be
5 observed via the Swiss-2DPAGE database (*See e.g.*, <http://www.expasy.ch>; Sanchez *et al.*, Electrophoresis 16:1131 [1995]). In addition, it is possible to view the latest protein list for the HEL cell in which 19 protein entries are shown (*See e.g.*, <http://www.expasy.ch/cgi-bin/get-ch2d-table.pl>).

Table 1. Thirty Eight Proteins Identified From HEL Cell IEF-NP RP HPLC Separation

Fraction #	Rotofor — pH	Retention Time (min.)	Enzyme *	MWt / pI: database calculated	Swiss, NCBI nr Accession #	Protein Name
3	4.20	5.34	trypsin	32575.2 / 4.64	P06748	NPM
3	4.20	6.20	trypsin	11665.0 / 4.42	P05387	60S RIBOSOMAL PROTEIN P2
3	4.20	6.91	trypsin	16837.7 / 4.09	P02593	CALMODULIN
3	4.20	10.15	trypsin	41737.0 / 5.29	P02570	BETA-ACTIN & GAMMA ACTIN
3	4.20	10.25	trypsin	61055.0 / 5.70	P10809	HSP-60
4	4.70	5.38	trypsin	32575.2 / 4.64	P06748	NPM
4	4.70	6.24	trypsin	35994.6 / 6.61	Q13011	ENOYL-COA HYDRATASE
4	4.70	7.07	trypsin	57914.2 / 7.95	P14786	PYRUVATE KINASE, M2
4	4.70	10.28	trypsin	61055.0 / 5.70	P10809	HSP-60
5	5.40	4.93	trypsin	22988.1 / 5.10	P52566	RHO GDI 2
5	5.40	10.15	trypsin	70898.4 / 5.38	P11142	HEAT SHOCK COGNATE 71 KD PROTEIN
8	5.60	4.99	trypsin	22988.1 / 5.10	P52566	RHO GDP-DISSOCIATION INHIBITOR 2
8	5.60	7.94	trypsin	69224.5 / 5.49	P23588	EIF-4B
8	5.60	10.35	trypsin	49831.3 / 4.79	P05217	TUBULIN BETA-2 CHAIN
9	5.80	6.90	trypsin	56782.7 / 5.99	P30101	ERP60
9	5.80	8.05	trypsin	17148.8 / 5.83	P15531	METASTASIS INHIBITION FACTOR NM23
9	5.80	8.50	trypsin	26669.6 / 6.45	P00938	TRIOSEPHOSPHATE ISOMERASE (TIM)
9	5.80	10.15	trypsin	41737.0 / 5.29	P02570	BETA-ACTIN & GAMMA ACTIN
11	6.20	5.62	trypsin	36926.7 / 6.37	S542020	(L32610) ribonucleoprotein
11	6.20	7.65	trypsin	33777.2 / 6.26	4885153	(X59656) CRKL
11	6.20	7.91	trypsin	22327.3 / 7.83	P04792	HEAT SHOCK 27
11	6.20	8.80	trypsin	74674.0 / 8.51	Q92935	EXOSTOSIN-L
11	6.20	9.22	trypsin	37374.9 / 5.85	P19883	FOLLISTATIN 1 AND 2 PRECURSOR
11	6.20	10.40	trypsin	47033.1 / 5.30	S032183	cargo selection protein TIP47
12	6.40	5.08	trypsin	13802.0 / 6.43	P49773	HINT
12	6.40	5.90	trypsin	70021.3 / 5.56	P54652	HEAT SHOCK 70 KD PROTEIN 2
12	6.40	7.48	trypsin	47169.2 / 7.01	P06733	ALPHA ENOLASE
12	6.40	8.12	trypsin	26669.6 / 6.45	P00938	TRIOSEPHOSPHATE ISOMERASE (TIM)
13	6.60	4.88	trypsin	48058.0 / 5.34	P05783	KERATIN, TYPE I CYTOSKELETAL I8
13	6.60	8.28	trypsin	62639.6 / 6.40	P31948	TRANSFORMATION-SENSITIVE PROTEIN
13	6.60	8.65	trypsin	34902.4 / 7.42	4505059	carcinoma-associated antigen GA733-2
15	7.00	4.70	trypsin	37429.9 / 8.97	P22626	NUCLEAR RIBONUCLEOPROTEINS A2/B1
15	7.00	8.70	trypsin	22391.6 / 8.41	P37802	SM22-ALPHA HOMOLOG
15	7.00	7.25	trypsin	47169.2 / 7.01	P06733	ALPHA ENOLASE
16	7.20	5.68	trypsin, Glu-C (E)	18012.6 / 7.68	P05092	PPIASE
16	7.20	6.89	trypsin	35940.7 / 7.18	P01861	IG GAMMA-4 CHAIN C REGION
16	7.20	7.24	trypsin	36053.4 / 8.57	P04406	GLYCERALDEHYDE 3-PHOSPHATE
16	7.20	7.45	trypsin, Glu-C (E)	47169.2 / 7.01	P06733	ALPHA ENOLASE
16	7.20	8.64	trypsin, Glu-C (E)	22391.6 / 8.41	P37802	SM22-ALPHA HOMOLOG
19	9.00	4.88	trypsin	38846.0 / 9.26	P09651	NUCLEAR RIBONUCLEOPROTEIN A1
19	9.00	5.13	trypsin	37429.9 / 8.97	P22626	NUCLEAR RIBONUCLEOPROTEINS A2/B1
19	9.00	5.85	trypsin	46987.1 / 7.58	P13929	BETA ENOLASE
19	9.00	7.47	trypsin	36053.4 / 8.57	P04406	GLYCERALDEHYDE 3-PHOSPHATE
19	9.00	8.70	trypsin	38604.2 / 7.58	P07355	ANNEXIN II
19	9.00	9.07	trypsin	22391.6 / 8.41	P37802	SM22-ALPHA HOMOLOG
19	9.00	10.53	trypsin	57221.6 / 9.22	P26599	PTB, NUCLEAR RIBONUCLEOPROTEIN I
20	9.50	4.46	trypsin, Glu-C (E)	38846.0 / 9.26	P09651	NUCLEAR RIBONUCLEOPROTEIN A1
20	9.50	4.67	trypsin, Glu-C (E)	37429.9 / 8.97	P22626	NUCLEAR RIBONUCLEOPROTEINS A2/B1
20	9.50	6.72	trypsin, Glu-C (E)	39420.2 / 8.30	P04075	FRUCTOSE-BISPHOSPHATE ALDOLASE A
20	9.50	7.06	trypsin	36053.4 / 8.57	P04406	GLYCERALDEHYDE 3-PHOSPHATE
20	9.50	7.39	trypsin, Glu-C (E)	47169.2 / 7.01	P06733	ALPHA ENOLASE
20	9.50	8.52	trypsin, Glu-C (E)	22391.6 / 8.41	P37802	SM22-ALPHA HOMOLOG
20	9.50	10.16	trypsin	44728.1 / 8.30	P05558	PHOSPHOGLYCERATE KINASE I
20	9.50	10.35	trypsin	57221.6 / 9.22	P26599	PTB, NUCLEAR RIBONUCLEOPROTEIN I

* Note that all proteins labelled only with trypsin were not digested with Glu-C (E)

Table 2. Nine Proteins Identified From HEL Cell CBB 2-D Gel

Gel Spot I.D. Number	Enzyme	MWt / pI: database calculated	SwissProt Accession #	Protein Name
g1	trypsin	18012.6 / 7.68	P05092	PPIASE
g2	trypsin	26669.6 / 6.45	P00938	TRIOSEPHOSPHATE ISOMERASE (TIM)
g3	trypsin	26669.6 / 6.45	P00938	TRIOSEPHOSPHATE ISOMERASE (TIM)
g8	trypsin	29032.8 / 4.75	P12324	TROPOMYOSIN, CYTOSKELETAL TYPE (TM30-NM)
g10	trypsin	32575.2 / 4.64	P06748	NPM
g11	trypsin	41737.0 / 5.29	P02570	BETA-ACTIN
g12	trypsin	61055.0 / 5.70	P10809	HSP-60
g13	trypsin	56782.7 / 5.99	P30101	ERP60
g14	trypsin	47169.2 / 7.01	P06733	ALPHA ENOLASE

C. IEF-NP RP HPLC versus 2-D SDS PAGE: Protein Loading and Quantification

Each separation method relies upon orthogonal mechanisms of separation generating a large number of isolated proteins. Protein profiles may be compared in terms of their pattern as well as the relative amounts of isolated proteins. It is shown, however, that the loadability of the liquid phase methods of the present invention greatly surpasses that of the gel phase.

The limit of detection for the gel method when stained with the silver stain is approximately 1 to 10 ng. The Coomassie blue stain can detect 100 ng of protein and the amount of protein in the spot can be quantified over 2.5 orders of magnitude. For the NP RP HPLC of standard proteins used in certain embodiments of the methods of the present invention, the limit of detection for the UV detector was 10 ng. The protein in the peak can be quantified from 10 ng up to 20 μ g providing 3.1 orders of magnitude. Quantification of an HPLC peak involves integrating the peak to find the area. For the gel, the spots must first be digitized and then this image must be analyzed to determine the integrated optical density of each spot of interest. The sensitivity of the UV detector in embodiments of the present invention utilizing HPLC is competitive with the silver stain and quantification is much simpler. The limits of detection for both the silver stained gel and the HPLC UV peak detection are mass dependent. For the gel, resolution and sensitivity are proportional to the molecular weight of the protein. For IEF-NP RP HPLC, the resolution and sensitivity are inversely proportional to the molecular weight of the protein. The gel appears to provide improved results for both acidic proteins and proteins above 50 kDa whereas IEF-NP RP HPLC performs better with proteins in the basic region and proteins that are below 50 kDa (*See e.g.*, Figure 1 and Figure 6). These results show the complementary nature of these two techniques where the gel and IEF-NP RP HPLC each provide important information of protein content.

In one experiment using the methods of the present invention, 23.5 mg of protein was loaded into the Rotofor, and after a five-hour IEF separation period fractions ranging from 2 to 4 mL were collected into polypropylene microtubes. The

amount of protein in the individual fractions ranged from 0.25 mg to 1.05 mg. Summing the amounts of protein in each fraction led to the determination that a total of 10.2 mg of protein was recovered from the Rotofor. This amount can be increased by increasing the amount of non-ionic detergent in the Rotofor buffer above the
5 current 0.1% level as well as by the addition of thiourea. In contrast, the amount of protein loaded on the 2-D gel in Figure 6 is 200 μ g. The amount of protein that actually makes it through the gel and focuses to a spot has not been quantified, relative to the amount of protein that is actually loaded on the gel, though it is known that many hydrophobic proteins are lost during the separation (Herbert, Electrophoresis
10 20:660 [1999]). The amount of protein that may theoretically be loaded on a gel ranges from 5 μ g up to 250 μ g whereas for IEF-NP RP HPLC the initial loading of protein may be as high as 1 gram. The amount of protein actually used to produce the separation shown in Figure 1 is only a fraction of the amount initially loaded into the Rotofor. The image in Figure 1 actually represents the separation of a total of 1 to 2
15 mg of protein though 10.2 mg of protein was recovered from the Rotofor. The loading of the HPLC column being used currently could be increased though the peak capacity may suffer. Alternatively a larger column could be used in series with the smaller column to allow for higher loadability with no loss of separation efficiency (See *e.g.*, Wall *et al.*, Anal. Chem., 71:3894 [1999]).

20 A 2-D gel provides a two dimensional separation from one initial loading of the cell lysate. The intensities of different spots on the same gel are representative of the relative protein abundances in the original lysate. However, in the IEF-NP RP HPLC methods of the present invention the proteins are loaded for the IEF and the HPLC separations so that the band intensities in the 2-D IEF-NP RP HPLC image
25 depend on the amount of protein loaded to the HPLC from each Rotofor fraction. Since the amount of material in each Rotofor fraction is different, the total area of each chromatogram was scaled to represent the total amount of protein that was recovered for each Rotofor fraction (See, Figure 3). The result is that the protein band intensities can be compared both within the Rotofor fraction and between the different
30 fractions.

In some embodiments of the present invention, 2-D gel techniques are used side-by-side with IEF-NP RP HPLC. In embodiments where specific proteins are desired for further characterization, the gel can provide information indicating which fraction obtained with IEF-NP RP HPLC contains the desired protein or proteins.

5 **D. Isoelectric Focusing: Liquid vs. Gel Phase**

The principal concern with liquid phase IEF is that the protein is not isoelectrically focused as effectively as it would be in a gel due to diffusion of the protein in solution. In the case of α -enolase, if one compares the liquid and gel phase images, it can be seen that in both cases substantial spreading of the protein occurs
10 over a wide pI range. This range spans from pI 6.5 to pI 9.5 in both the liquid phase and the gel phase. For more acidic proteins such as β -actin, it appears that in the liquid phase the protein is more dispersed in the pI dimension than for the corresponding gel separated protein. Both methods provide a reasonably accurate assessment of the pI of the protein of interest. Referring to Table 1, it can be seen
15 that as the Rotofor fraction pH increases, so generally does the pI of identified proteins therein. The pH of fraction 3 measures 4.2 and the proteins identified from this fraction range in pI from 4.09 to 5.7. The pH of fraction 9 was 5.8 and the proteins identified from that fraction ranged from 5.29 to 6.45. The pH of fraction 16 was 7.2 and the pI range of proteins found there ranged from 7.01 to 8.93. The pI accuracy
20 therefore ranges from +/- 0.65 to 1.73 pI units. This is comparable to the carrier ampholyte based gel. It should be remembered that the pI of a given protein may vary significantly due to post-translational modifications such as phosphorylation and glycosylation, as well as to artifactual modifications such as carbamylation and oxidation.

25 **E. Second Dimension Liquid Separation**

Fraction 16, Figure 4, may be used as an example of the quantification of isolated proteins. For fraction 16, the volume of injection was 160 μ L. This means that if the concentration of protein was 201.4 μ g/mL then the amount of protein loaded

was 32.2 μg . The chromatogram was integrated using Microcal Origin software and the total area was determined to be 97.78. The areas of peaks 16E and 16J were 3.68 and 5.41 respectively. Dividing the peak area by the total area gives the fraction of protein represented by the peak. Therefore, if one assumes 100% protein recovery, the amount of PPIASE (16E, $t_R = 5.68$) in 16 was $(0.0376 * 32.2 \mu\text{g})$ 1.21 μg and the amount of α -enolase (16J, $t_R = 7.45$) was $(0.0553 * 32.3 \mu\text{g})$ 1.78 μg . The peak areas were generated by absorbance of 214 nm light at the amide bonds of the proteins and so should offer low selectivity thereby allowing for a good measure of the amount of protein in the peak regardless of the type of protein.

Figure 4 shows how the continuous integration of the chromatogram may be used to estimate the amount of protein isolated in a given peak. The peak area line is simply converted into mass units from which the observer can measure the change in the vertical mass axis that occurs over the width of the peak of interest. If one knows the initial concentration of protein in the cell lysate and the number of cells that were lysed, a quantitative comparison of different cell lysates can be made. This comparison is important to studying changes in protein expression levels due to some disease state or pharmacological treatment. In gel work, a technique used for protein quantification in different samples is to normalize the integrated optical density of the spot of interest to that of standard proteins whose expression levels are thought to be constant. In this way any experimental variation in spot intensity can be corrected. This same method is applied to the IEF-NP RP HPLC image to allow for reliable quantification of proteins of interest such that changes in expression level are quantitatively observed.

The assumption in these experiments is 100% protein recovery. One can determine the actual % recovery of protein and the dependence on elution time. Typical protein recoveries have been shown to range from 70 to 95% in NP RP HPLC (Wall *et al.*, *Anal. Chem.*, 71:3894 [1999]) and so, with a more likely percent recovery of 80%, the amount of PPIASE and α -enolase in fraction 16 would be estimated to be 1.0 μg and 1.42 μg , respectively.

F. Rotofor Fraction Analysis by NP RP HPLC vs. 1-D SDS PAGE

NP RP HPLC provides highly efficient protein separations (*See e.g.*, Chen *et al.*, *Rap. Comm. Mass Spec.*, 12:1994 [1998]; Wall *et al.*, *Anal. Chem.*, 71:3894 [1999]; and Chong *et al.*, *Rap. Comm. Mass Spec.*, 13:1808 [1999]), and is a far easier method to automate as compared to gels in terms of injection, data processing and protein collection. In addition the NP RP HPLC separations provided by the present invention are 70 times faster than the equivalent separation by 1-D SDS-PAGE, which requires 14 hours. In the experiments described above, the NP RP HPLC method has greater resolving power generating 35 bands where the 1-D gel generates only 26 bands. A direct comparison of the two methods, as shown in Figure 7, reveals that the NP RP HPLC bands are much narrower than those of the 1-D SDS PAGE over a similar molecular weight range. Also it is clear that as molecular weight decreases, the 1-D gel band width increases substantially. In NP RP HPLC the opposite trend occurs where the lower molecular weight proteins show improved resolution and sensitivity. This image may appear to show that the NP RP HPLC separation fails with larger proteins as there are few bands in the upper region of the image. However, this is not the case as it is important to remember that the vertical dimension for NP RP HPLC is not protein molecular weight but rather protein hydrophobicity. This is evidenced by the observation of the elution of bovine serum albumin (66 kDa), a relatively hydrophilic protein, half way up an image.

G. Elution Time Prediction for Known Target Protein

One of the advantages of the 2-D gel is that the vertical coordinate of the gel may be used to estimate the molecular weight of the protein with a +/- 10% error. The position of a protein of interest can therefore be estimated before the protein is identified from the gel. In an attempt to correlate elution time in the methods of the present invention with the mass of the protein, a linear fit to a plot of percent acetonitrile at time of elution (%B) versus the log(MWt)/protein polar ratio was generated. The polar ratio (PR) is the number of polar amino acids divided by the total number of amino acids in the protein and the molecular weight is in kDa. The

proteins used for this plot were four of the standards listed in Figure 1 as well as a sampling of six of the proteins from Table 1 (HSP60, β -actin, TIM, α -enolase, PPIASE and glyceraldehyde-3-phosphate). The resulting equation (equation 1: $\%B/100 = 0.079805 * (\log MWt)/PR + 0.077686$, ($R = 0.9677$, $SD = 0.014722$, $N = 7$)) is used to predict the elution time of target proteins. For HSP60, β -actin and α -enolase the experimental elution times were 10.28, 10.15 and 7.25 respectively. The predicted elution times were 10.20, 10.13 and 9.78. In the cases of HSP60 and β -actin the prediction works well, whereas for α -enolase the prediction is not as good. While not precise, this prediction does give some idea of when a protein will elute such that a given target protein, for which the molecular weight and hydrophobicity are known, can be found more readily.

H. Protein Identification by Enzymatic Digestion, MALDI-TOF MS and MSFit Database Searching

The proteins that were identified from a representative sampling of the bands from the IEF-NP RP HPLC separation are listed in Table 1. A sampling of approximately 80 proteins from 12 of the Rotofor fractions were digested and their peptide mass maps successfully obtained by MALDI-TOF MS. Of these 80, 38 different proteins were identified. In this case, identifying roughly 50% of the proteins searched is to be expected as not all the proteins are in the available databases. Similar results were observed for proteins analyzed from 2-D gels of the HEL cell samples. The current table in Swiss-2DPAGE lists 19 protein entries for the HEL cell. Of these 19 proteins, five were identified from the IEF-NP RP HPLC separation. In the gel, these same five proteins were also identified.

In general, it appears that the gel MSFit results are better than those from the liquid phase. This can be attributed to the fact that the gel proteins were reduced and alkylated with DTE and iodoacetamide respectively prior to the running of the second dimension. This step would help insure that all disulfide bonds are broken and optimal proteolysis is produced. Thus, this derivatization step can be added to the IEF-NP RP HPLC method, by performing the reduction and alkylation step prior to

NP RP HPLC or during cell lysis. Nevertheless, in some cases the IEF-NP RP HPLC digestions surpassed those from the gel in coverage and quality. This is evidenced in Figure 8, which shows a direct comparison of the MALDI-TOF MS for α -enolase as isolated via the IEF-NP RP HPLC method and the gel method. These mass spectra were calibrated externally at first and the mass profiles used to search the Swiss protein database with a mass accuracy of 400 ppm. These searches gave strong hits to α -enolase for both the gel and the liquid protein digests. Each mass spectrum was then recalibrated internally using matched peptide peaks from the initial externally calibrated match. The new peak table was then used to search the same Swiss protein database but with 200 ppm mass accuracy. Figure 8 clearly shows that the digestion from the liquid phase is improved compared to that from the gel. The IEF-NP RP HPLC mass spectrum matches to 60% of the protein sequence whereas that from the gel matches to 49%. Achieving a match to 60% of the sequence of a 47 kDa protein is very unusual for MALDI-TOF MS analysis and represents a significant improvement over gel digests. Although the present invention is not limited to any particular mechanism, the increase in sequence coverage may be due to the fact that the protein is digested in the liquid phase, is relatively pure, and because the peptides are not lost due to being embedded inside the gel piece. Also if one observes the level of methionine oxidation in the peak that matches to T163-179, it is clear that the protein isolated by IEF-NP RP HPLC is far less oxidized than that from the gel.

Many of the NP RP HPLC chromatograms contain some peaks that are not fully resolved to baseline. This need not be a problem as partially resolved proteins can still be effectively identified using MALDI-TOF MS analysis. In Rotofor fraction 3 there are peaks at 10.15 minutes and 10.25 minutes (*See*, Table 1). These peaks are only resolved to 50% above the baseline and yet it is clear that the peak eluting at 10.15 minutes is β -actin and the peak eluting at 10.25 minutes is HSP-60. Note that the predicted elution times for these proteins are 10.13 and 10.20 minutes respectively. As proteins can be identified from partially resolved peaks, faster separations with more rapid gradients are possible. The reproducibility of the pattern of bands can be determined by looking at the retention times for particular proteins as observed from

different Rotofor fractions. β -actin elutes at 10.15 minutes in both fractions 3 and 9; α -enolase elutes at 7.25, 7.45 and 7.39 minutes in fractions 12, 16 and 20 respectively; and HSP-60 elutes at 10.28 and 10.25 minutes in fractions 3 and 4 respectively.

Clearly, with +/- 0.1 minutes variation in the retention times, these separations are quite reproducible from run to run.

Thus, the methods of the present invention have been shown to provide advantageous methods for the reproducible separation of large numbers of proteins. In the human erythroleukemia cell lysate example, the methods are capable of resolving 700 bands with a rapid gradient, and 1000 bands with a longer gradient. There were 38 different proteins tentatively identified, by MALDI-TOF MS and MSFit database searching, after analysis of a fraction of these bands. This compares favorably with the 19 different proteins that have been identified to date from the 2-D gel. Some of the proteins found in the human erythroleukemia cell lysate; including α -enolase (Rasmussen *et al.*, Electrophoresis 19:818 [1998] and Mohammad *et al.*, Enz. Prot., 48:37 [1994]), glyceraldehyde-3-phosphate dehydrogenase (Bini *et al.*, Electrophoresis 18:2832 [1997] and Sirover, Biochim. Biophys. Acta 1432:159 [1999]), NPM (Redner *et al.*, Blood 87:882 [1996]), CRKL (ten Hoeve *et al.*, Oncogene 8:2469 [1993]), and heat shock protein (HS27) (Fuqua *et al.*, Cancer Research 49:4126 [1989]), have been linked to various forms of cancer. NPM and CRKL have been linked specifically to leukemias.

The proteins identified in one exemplary experiment ranged from 12 kDa up to 75 kDa (although broader ranges are contemplated by the present invention); this range may include many of the proteins of interest to current research involving protein profiling, identification and correlation to some disease state or cell treatment. In sharp contrast to 2-D gels, this method is well-suited to automation. Mass spectrometric methods can be applied, such as ESI-MS and MALDI-TOF MS, to the detection of whole proteins and protein digests. Most importantly, the methods of the present invention provide an alternative 2-D protein map to the traditional 2-D gel and appears to improve results for lower mass proteins and more basic proteins. A key advantage of the liquid 2-D separation is that the end product is a purified protein in

the liquid phase. Also, since the initial protein load can be fifty times that of the gel, the amount of a target protein that may be isolated by one IEF-NP RP HPLC separation is potentially fifty times higher than that obtainable from a 2-D gel separation. Additionally, in the case that the investigator is interested in specific proteins where the pI is known, this method may be used to isolate and identify the target protein in less than 24 hours, since only the fraction of interest need be analyzed via the second dimension separation. The gel-based method would require three days to achieve the same result.

I. Identification of Novel Tumor Antigens

There is substantial interest in identifying tumor proteins that are immunogenic. Autoantibodies to tumor antigens and the antigens themselves represent two types of cancer markers that can be assayed in patient serum and other biological fluids. IEF-NP RP HPLC-MS has been implemented for the identification of tumor proteins that elicit a humoral response in patients with cancers. The identification of proteins that specifically react with sera from cancer patients was demonstrated using this approach. Solubilized proteins from a tumoral cell line are subjected to IEF-NP RP HPLC-MS. Individual fractions defined on the basis of pI range are subjected simultaneously to one-dimensional electrophoresis as well as to HPLC. Sera from cancer patients are reacted with Western blots of one-dimensional electrophoresis fractions. One band which reacted specifically with sera from lung cancer patients and not from controls was found to contain both Annexin II and aldoketoreductase. The ability to subfractionate further proteins contained in this fraction by HPLC led to the identification of Annexin II as the tumor antigen that elicited a humoral response in lung cancer patients.

J. Comparative Analysis

As is clear from the above description, the methods of the present invention offer the opportunity to compare protein profiles between two or more samples (*e.g.*, cancer vs. control cells, undifferentiated vs. differentiated cells, treated vs. untreated

cells). In one embodiment of the present invention, the two samples to be compared are run in parallel. The data generated from each of the samples is compared to determine differences in protein expression between the samples. The profile for any given cell type may be used as a standard for determining the identity of future
5 unknown samples. Additionally, one or more proteins of interest in the expression pattern may be further characterized (*e.g.*, to determine its identity). In an alternative embodiment, the proteins from the samples are run simultaneously. In these embodiments, the proteins from each sample are separately labeled so that, during the analysis stage, the protein expression patterns from each sample are distinguished and
10 displayed. The use of selective labeling can also be used to analyze subsets of the total protein population, as desired.

As is clear from the above description, the methods and compositions of the present invention provide a range of novel features that provide improved methods for analyzing protein expression patterns. For example, the present invention provides
15 methods that combine IEF, resulting in pI-focused proteins in liquid phase fractions, with nonporous RP HPLC to produce 2-dimensional liquid phase protein maps. The data generated from such methods may be displayed in novel and useful formats such as viewing a collection of different pI NP RP HPLC chromatograms in one 2-D image displaying the chromatograms in a top view protein band format, not the traditional
20 side view peak format. As shown in Figure 2, the side view peak format is shown to the left and the top view band format is shown to the right. The present invention also provides detergents that are compatible with automated systems employing multi-phase separation and detection steps.

The present invention provides additional characterization steps, including the
25 identification of proteins separated by IEF-NP RP HPLC using enzymatic digestions and mass spectrometric analysis of the resulting peptide mass fingerprints. Proteins may be detected to determine their molecular weights by analyzing the effluent from the HPLC with either off-line collection to a MALDI plate (Perseptive) or on-line analysis using orthogonal extraction time-of-flight. The data generated from such
30 methods may be displayed in novel and useful formats such as using the data from the

MALDI or LCT generated protein molecular weights to generate total ion chromatograms (TIC) that would be virtually identical to the original UV-absorbance chromatograms. The signal of these chromatograms would be based on the number of ions generated from the HPLC effluent of a given group of pI-focused proteins, not by absorption of light. These chromatograms are plotted in the same 2-D top view band format as mentioned above. These methods allow one to fully integrate and deconvolute each of the TIC's generated to display complete mass spectra of each collection of pI-focused proteins. The methods also allow the display of all the integrated TIC's in one 2-D image where the vertical dimension is in terms of protein molecular weight and the horizontal dimension is in terms of protein pI. The protein mass spectra appears as bands as they are also viewed from the top. This image would therefore also contain quantitative information (in the case of the LCT) and so the bands would vary in intensity depending on the amount of protein present.

The liquid phase methods for protein mass mapping would also allow for collection of protein fractions to microtubes such that the proteins could be digested and the peptide mass maps analyzed to determine the identity of said proteins simultaneously. Laser induced fluorescence (LIF) detection schemes are used in conjunction with this method to increase the overall sensitivity by three orders of magnitude. The liquid phase LIF detector provides more sensitive fluorescence detection than in the gel as there would be no gel background fluorescence. This LIF detection method could be used in a number of ways including, but not limited to:

- 1) Combining equal amounts of two cell lysates that have each been previously stained with a different fluorescent dye followed by use of a dual fluorescence detector to simultaneously detect the same proteins from two different cell lysates. This would allow for very accurate comparisons of the relative amounts of proteins found for different cell lines or tissues; and
- 2) Using a fluorescently tagged antibody to label specific target proteins in a cell lysate such that they can be targeted for thorough analysis without looking at all the other proteins.

The methods and apparatuses of the present invention also offer an efficient system for combining with other analysis techniques to obtain a thorough characterization of a given cell, tissue, or the like. For example, the methods of the present invention may be used in conjunction with genetic profiling technologies (*e.g.*,
5 gene chip or hybridization based nucleic acid diagnostics) to provide a fuller understanding of the genes present in a sample, the expression level of the genes, and the presence of protein (*e.g.*, active protein) associated with the sample.

II) Improved Elution Techniques Using Chromatofocusing

As described above, the present invention provides novel liquid
10 chromatographic methods involving a 2-column 2-D separation of proteins from whole cell lysates followed by on-line mass mapping with by mass spectrometry (*e.g.*, using ESI-*oa*TOF MS as described in detail below). It is a 3-D protein analysis system as proteins are separated based upon, for example, their isoelectric points (*pI*) in the first LC dimension.

15 The present invention further provides novel techniques for eluting proteins from a separation apparatus (*e.g.*, the first phase separation apparatus). For example, in one embodiment of this technique, the proteins eluted from the first dimension are "peeled off" from the column according to their pH, either one pH unit or fraction thereof, at a time--referred to as chromatofocusing (CF). These focused liquid
20 fractions are then separated according to their hydrophobicity and size (or other desired properties) in the second dimension. Liquid fractions from, for example, NP-RP-HPLC can be conveniently analyzed directly on-line using mass spectrometry (*e.g.*, ESI-*oa*TOF) to obtain their molecular weight and relative abundance, which provides a third dimension. As a result, a virtual 2-D protein image is created and is analogous
25 to a 2-D gel image. Furthermore, this 2-D protein image includes vital information such as the *pI*, hydrophobicity, molecular weight, and relative abundance. This "Protein Peeling" 2-D LC-MS method is a practical alternative to 2-D gels in order to study protein expression between normal and disease whole cell lysates, for example.

This whole system can be fully automated and integrated into a single unit for rapid proteome analysis, providing a more accurate and less expensive automation technology compared to automation technologies for use with 2-D gels.

5 An exemplary embodiment of the chromatofocusing techniques of the present invention are provided in Example 7. Data from these experiments is shown in Figures 14-16. Figure 14 shows the CF profile of MCF-10A whole cell lysate (pH 7 to 4). Fractions 1 to 3 were further analyzed with NP-RP-HPLC-ESI-*oa*TOF MS (described in detail below). Figures 15A-C show the NP-RP-HPLC-ESI-*oa*TOF TIC (total ion count) profile of the three fractions from Figure 14: (A) fraction 1 (pH 6.75
10 – 6.55); (B) fraction 2 (pH 5.50 – 5.25); and (C) fraction 3 (pH 5.20 – 4.90). By integrating and deconvoluting the TIC profiles with the *MaxEnt1* software (described in detail below), the mass spectra for all three fractions are displayed in a 2-D format as shown in Figure 16. Figure 16 shows the integrated TIC in one 2-D protein map where the vertical column is the molecular weight while the horizontal dimension is
15 the protein *pI* point. This map also contains the relative abundance information whereby the bands vary in intensity (shades of gray) depending on the amount of the protein present.

The data generated by CF-NP-RP-HPLC-ESI-*oa*TOF MS can be presented as 2-D maps or 2-D images much like the traditional 2-D gel images. For example, in
20 some embodiments, the chromatograms, TICs, integrated and deconvoluted mass spectra are converted into the ASCII format before being plotted vertically, using a 256-step gray scale, such that peaks are represented as darkened bands against a white background. This scale comes in a variety of color formats. Therefore, this 2-D map provides vital information on *pI*, hydrophobicity, molecular weight as well as the
25 relative abundance of separated proteins. This map can also be adjusted by zoom into a specific area of interest, for a more detailed image of all the bands therein. All the information gathered from this 2-D map can be used to examine protein expression in a cell system due to the disease state, pharmaceutical treatment or environmental change. Since the image is automatically digitized, it can be easily stored and the

bands can be hyperlinked to other experimental results or related data. As a result, all the information is available from the original image.

The use of chromatofocusing with the separation, analysis, and display methods of the present invention provide a number of important advantages not previously available. For example, by combining chromatofocusing with a second separation phase (*e.g.*, NP-RP-HPLC) and mass spectrometry analysis, a 2-D liquid phase protein map is generated which is analogous to a 2-D gel. In preferred embodiments, this is a multi-dimensional liquid chromatography (LC) whereby both chromatographic techniques are performed on-line (*i.e.*, in an automated fashion) between two or multiple LC units with a switching valve to deliver fractions from CF to, for example, NP-RP-HPLC. Proteins are "peeled off" the CF column according to their pH, one pH unit or fraction thereof, at a time. This "peeling" feature allows for further focusing of the protein bands at their respective *pI* regions. The protein concentration of each *pI* band is thus enhanced during elution. As with the method described above, buffers can be used that are compatible with each step of the process. For example, in some embodiments, the sample preparation and CF separation involves the use of guanidine-hydrochloride and a nonionic detergent (*e.g.*, *n*-octyl β -D-glucopyranoside) that is compatible with the NP-RP-HPLC and ESI-*oa*TOF MS.

III) Mass Spectroscopic Analysis and 2-D Display Systems and Methods

In some preferred embodiments of the present invention, separated proteins are analyzed by mass spectrometry to facilitate the generation of detailed and informative 2-D protein maps. The present invention is not limited by the nature of the mass spectrometry technique utilized for such analysis. For example, techniques that find use with the present invention include, but are not limited to, ion trap mass spectrometry, ion trap/time-of-flight mass spectrometry, quadrupole and triple quadrupole mass spectrometry, Fourier Transform (ICR) mass spectrometry, and magnetic sector mass spectrometry. The following description of mass spectroscopic analysis and 2-D protein display is illustrated with ESI *oa* TOF mass spectrometry.

Those skilled in the art will appreciate the applicability of other mass spectroscopic techniques to such methods.

In some embodiments of the present invention, ESI or TOF mass spectrometry is used following two dimensional protein separation to provide an accurate protein separation map. For example, in one embodiment of the present invention, proteins were analyzed from human erythroleukemia (HEL) cells. The human erythroleukemia (HEL) cell line was obtained from the Department of Pediatrics at The University of Michigan. HEL cells were cultured according to the methods described in Example 1. A preparative scale Rotofor (Biorad) was used in the first dimension separation. In this experiment, 20 mg of protein was loaded. The proteins were separated by isoelectric focusing over a 5 hour period with slight modifications to the Rotofor methods described elsewhere herein. The separation temperature was 10°C, and the separation buffer contained 0.5 % n-octyl β -D-glucopyranoside (OG) (Sigma), 6 M urea (ICN), 2 M thiourea (ICN), 2 % β -mercaptoethanol (Biorad) and 2.5 % Biolyte ampholytes, pH 3.5-10 (Biorad).

The procedure used for running the Rotofor (Rotofor Purification System, Biorad) was a modified version of the standard procedure described in the manual from Biorad. The starting power, voltage and current were 12 W, 400 V and 36 mA respectively. The ending power, voltage and current were 12 W, 1000 V and 5 mA respectively. The 20 fractions contained in the Rotofor were collected simultaneously into separate vials using a vacuum source attached by plastic tubing to an array of 20 needles which were punched through a septum. The Rotofor fractions were aliquotted in 400 μ L amounts into polypropylene micro-centrifuge tubes and stored at -80°C for further analysis as desired. The pH of the fractions was determined using pH indicator paper (Type CF, Whatman). Fractions from the Rotofor were quantified using a Bradford assay (*See e.g.*, Wall *et al.*, Anal. Chem., 72:1099 [2000]).

For NPS RP HPLC, separations were performed at a flow rate of 0.4 mL per minute on an analytical (3.0 * 33 mm) NPS RP HPLC column containing 1.5 μ m C18 (ODSI) non-porous silica beads (Eichrom Technologies). The use of the 3 mm column provided more than sufficient sensitivity with the use of the LCT as well as

reduced solvent consumption. The column was placed in a column heater (Timberline, Boulder CO) and maintained at 65°C. The separations were performed using water/acetonitrile (0.1 % TFA, 0.3% formic acid) gradients. The gradient profile used was as follows: 1) 0 to 20 % acetonitrile (solvent B) in 1 minutes; 2) 20 to 30 % B in 2 minutes; 3) 30 to 54 % B in 8 minutes; 4) 54 to 65% B in 1 minute; 5) 65 to 100 % B in 1 minute; 6) 100 % B in 3 minutes; 7) 100 to 5 % B in 1 minute. The effective start point of this profile was one minute into the gradient due to a one-minute dwell time. The acetonitrile was 99.93 +% HPLC grade (Sigma), the TFA was from 1 mL sealed glass ampules (Sigma) and the formic acid was ACS grade (Sigma). The non-ionic detergent used was n-octyl β -D-galactopyranoside (OG) (Sigma). The HPLC instrument used was a Beckman model 127s/166 and the peaks were detected on-line by a commercial ESI oa TOF/MS (LCT, Micromass, Manchester U.K.). In preferred embodiments, a detergent is used throughout the separation and detection steps that is compatible with the steps of RP HPLC and ESI oa TOF/MS (e.g., detergents of the formula n-octyl (SUGAR)pyranoside).

The ESI oa TOF/MS analyses were performed on a Micromass LCT equipped with a reflectron, a 0.5 meter flight tube and a dual micro-channel plate detector. The instrument produced protein mass spectra with a mass resolution of 5000 (FWHM). The flow from the HPLC column eluent was split to the ESI stainless steel capillary at a 1:1 ratio leaving a flow to the mass spectrometer of 0.2 mL/minute. The source temperature was held at 150°C, the desolvation temperature was 400°C, the nebulizer gas (N₂) was left at 50% maximum flow and the desolvation gas was held at 600 L/minute. The capillary voltage was held at +2500 V and the sample cone voltage was held at +45 V. The extraction cone was held at +3 V. The RF voltage was set at 1000 V with the first hexapole being biased to a positive DC offset of +7 V and the second hexapole being biased to a negative DC offset of -2 V. The detector voltage was held at 2900 V. Data was acquired for a maximum mass/charge range of 5000 resulting in a pusher cycle time of 90 μ s. The data was stored to the ECP at a rate of 1 Hz and then transferred from this data-collecting computer to the main data analysis computer for generation of the data files and TIC.

Software used to analyze the mass spectra was the MaxEnt (version 1) software and Mass Lynx version 3.4 (Micromass). Typical deconvolution was performed with a wide target mass range, 1 Dalton resolution, 0.75 Da peak width and 60% peak height values. All deconvoluted mass spectra from a given TIC were added together to produce one mass spectrum for each TIC. The TIC mass spectra from each of the Rotofor fractions were then input to the 2D mapping software (available from Dr. Stephen J. Parus, University of Michigan, Department of Chemistry, 930 N. University Ave., Ann Arbor, MI 48109-1055).

The 2-D image in Figure 9 shows protein molecular weight in the vertical dimension and protein pI in the horizontal dimension. Individual proteins are represented as bands within the grayscale image. Protein identities were matched to this image by overlaying a virtual map of all proteins previously identified via the NPS RP HPLC separation method described above and digest analysis with MSFit database searching.

The experimental mass values were typically within 1 to 3 parts per thousand of the value recorded in the SWISS-PROT database. The pI could be estimated to within 0.01 to 0.5 pI units using intensity profiling as described below. Each vertical lane represents, in band format, all proteins observed via LCT mass spectral detection from the NPS RP HPLC analysis of that particular Rotofor fraction. The NPS RP HPLC separations were performed on from 17 to 60 µg of protein per Rotofor fraction. The bands in the image vary in gray scale intensity according to the intensity of the source molecular weight peaks. This image has been magnified in the intensity dimension by allowing virtual saturation of the signal of the more abundant proteins. The magnification factor is 27X or 53615/2000 (max intensity/magnification intensity). The intensity has a linear dynamic range of at least 3 orders of magnitude. Some of the same protein patterns can be seen in both the liquid phase separation and a 2D gel image from Swiss-Prot (<http://expasy.cbr.nrc.ca/ch2dothergifs/publi/elc.gif>). Five of the nineteen proteins identified in the 2D gel image also were found in the liquid phase separation. When comparing these images it must be kept in mind that the mass

scale is linear from the liquid phase separation and logarithmic in the gel phase separation.

The pI of proteins isolated in the 3D liquid separation method can be estimated by observing the intensity of a given protein peak over a range of pI fractions. As a
5 protein may spread anywhere from 2 to 6 pI fractions due to diffusion and basic cathodic drift, it should be most abundant in that fraction that is closest to its own pI. This can be observed in the zoom image of Figure 10 (*See also*, zoom image of Figure 13). Using this approach, the pI of alpha-enolase is estimated to be 7.0 (database value of 7.01), and the pI of glyceraldehyde 3-PO₄ dehydrogenase is estimated to be
10 8.0 (database value of 8.57). This acidic shift may be due to a post-translational modification such as phosphorylation or glycosylation.

The protein molecular weights were determined by MaxEnt deconvolution of multiply charged protein umbrella mass spectra that were obtained by combining anywhere from 10 to 60 seconds of data from the initial total ion chromatogram (TIC).
15 The umbrella for beta and gamma actin is shown in Figure 11A, each form of actin being labeled with the charge state. Figure 11B shows the resulting molecular weight mass spectrum for actin where the two forms of actin are separated. Note that the two forms of actin are clearly resolved from one another unlike in gel images where the actin spot always represents the co-migration of beta and gamma actin. A useful
20 feature of the liquid phase method of the present invention is the capability of the high resolution mass spectrometry to quantitate which allows the observer to record relative levels of each form of a given protein. Consequently, it is contemplated that one can determine the relative abundances of the phosphorylated and non-phosphorylated forms of a given protein. In addition, post-translational modifications such as
25 phosphorylation can be found by searching the data for intervals of some integer value times 80 Da.

Figure 12 shows the traditional peak view format of one of the Rotofor fraction's combined molecular weight mass spectra. All proteins were deconvoluted and then added together into one mass spectrum. There are 44 unique protein
30 molecular weights observed in this mass spectrum. Assuming similar numbers of

unique masses in all 15 of the Rotofor fractions analyzed herein, and accounting for longitudinal diffusion between fractions, it is estimated that approximately 220 unique protein masses in the image from a pI of 4.1 to a pI of 8.75. The Rotofor produces 20 fractions, though only 15 were analyzed in this work, so that around 300 unique masses should be observed in the full analysis of all Rotofor fractions. It is contemplated that lower level proteins not obtained in the above experiment can be obtained using improved HPLC gradients, 53 mm long columns and more detailed MaxEnt analyses. Using such methods, it is contemplated that the number of unique masses will be around 750.

As shown in the above experiments, the 2D protein image from the IEF-NPS RP HPLC-ESI or TOF/MS separation of the human erythroleukemia cell lysate provides high mass resolution and high accuracy imaging of the proteins. The mass resolution allows the image to show very different forms of the same protein that have small differences in mass. With a mass resolution of 5000 Da, a 50000 Da protein can be resolved from a 50010 Da protein. Clearly, single phosphorylations on entire proteins can be observed with this level of resolution. Quantitative comparison between 2-D images can be achieved by spiking samples with known amounts of standard proteins and normalizing images through landmark proteins. Thus, the observer can detect significant abundance changes in the protein profiles of different samples. The differences can then be targeted for more detailed analysis. For example, protein bands on the image can be hyper-linked to other experimental results, obtained via analysis of that band, such as peptide mass fingerprints and MSFit search results. Thus all information obtained about a given 2-D image, including detailed mass spectra, data analyses and complementary experiments (immuno-affinity, peptide sequencing) can be accessed from the original image.

Having identified and characterized the proteins that have changed in abundance due to some disease state or drug treatment, it is possible to identify biomarkers for disease states as well as drug targets for pharmaceutical agents and monitor the presence of, or change in, such markers in a particular biological sample (e.g., tissue samples with and without exposure to a candidate drug). Indeed, drug

screening and diagnostic techniques can be automated using the systems and methods of the present invention, wherein cells (*e.g.*, experimental and control cells) are cultured, treated, and lysed using robotics and wherein the lysate is fed into the automated separation and analysis systems of the present invention.

5 As is clear from the above description, the methods and systems of the present invention provide a range of novel features that provide improved methods for analyzing protein expression patterns. For example, the present invention provides a combination of IEF, resulting in pI-focused proteins in liquid phase fractions, with nonporous RP HPLC and ESI oa TOF/MS to produce a 2-dimensional liquid phase
10 protein map image analogous to that of a 2-D gel. These methods allow the identification of proteins separated by IEF-NPS RP HPLC using enzymatic digestions and mass spectrometric analysis of the resulting peptide mass fingerprints and correlation of this data with the pI and molecular of the protein found via the whole protein 3-D separation method. In some improved display embodiments of the present
15 invention, one can view a collection of different IEF-NPS RP HPLC-ESI oa TOF/MS chromatograms in one 2-D image displaying the mass spectra in a top view protein band format, not the traditional side view peak format. The methods also allow the detection of proteins and determination of their molecular weights by analyzing the eluent from the HPLC with computational (*e.g.*, on-line) analysis using ESI oa
20 TOF/MS.

 The IEF-NPS RP HPLC-ESI oa TOF/MS method also allows one to fully integrate and deconvolute each of the TIC's generated to display complete mass spectra of each collection of pI-focused proteins. The method also allows the display of all the integrated TIC's in one 2-D image where the vertical dimension is in terms
25 of protein molecular weight and the horizontal dimension is in terms of protein pI. In such displays, the protein mass spectra appear as bands as they will also be viewed from the top. This image would therefore also contain relative quantitative information wherein the bands vary in intensity depending on the amount of protein present. The use of liquid phase separation techniques with the method allows for
30 collection of protein fractions to micro-tubes or 96-well plates such that the proteins

could be digested and the peptide mass maps analyzed to determine the identity of said proteins simultaneously.

IV) Automated 3D HPLC/MC Methods for Rapid Protein Characterization

In some embodiments, the present invention provides an automated system for the separation and identification of protein samples based on multiple physical properties. Accordingly, in some embodiments, the protein separation and analysis techniques described in the preceding sections are automated into one integrated, on-line system. Protein samples are separated in a first phase and a second orthogonal phase, followed by mass spectroscopy analysis. In preferred embodiments, all of the steps are automated and coordinated through an automated sample handler and a centralized control network.

Accordingly, in some embodiments, the entire separation and characterization process is controlled through one centralized control network. The network is integrated with all of the apparatus and software used for the automated process. In some preferred embodiments, the centralized control network includes a computer system. The use of a centralized control network allows for the entire separation and characterization process to be controlled from one computer terminal by one operator. The network directs sample through the appropriate separation phases. The network then controls the transfer of protein information to analysis software. The analysis software is integrated into the network and can be programmed to generate a customized report based on the information required by the user.

A. Protein Separation

As described above, the present invention provides methods for the separation of protein samples in two phases. In preferred embodiments, the methods are orthogonal, and thus allow for the generation of a two-dimensional map. In some preferred embodiments, the present invention further provides methods of automating the two phase separation.

1. Separation in a First Phase .

The automated separation methods of the present invention may be used on any suitable protein sample. As discussed above, in some embodiments, the sample is solubilized in a buffer comprising a compound of the formula n-octyl SUGAR
5 pyranoside (*e.g.*, including, but not limited to, n-octyl β -D-glucopyranoside and n-octyl β -D-galactopyranoside).

The first dimension of the automated separation process separates proteins based on a first physical property. For example, in some embodiments of the present invention proteins are separated by charge (*e.g.*, ion exchange chromatography). In
10 some preferred embodiments, cation exchange chromatography is used to separate positive proteins and anion exchange chromatography is used to separate negatively charged proteins. However, the first dimension may employ any number of separation techniques including, but not limited to, ion exclusion, isoelectric focusing,
normal/reversed phase partition, size exclusion, ligand exchange, liquid/gel phase
15 isoelectric focusing, and adsorption chromatography.

In some preferred embodiments, the first separation phase is conducted in the liquid phase. In some embodiments, the first phase is ion exchange. In such
embodiments, it is preferred that samples are de-salted prior to the second separation phase. In some embodiments, desalting is performed on an automated solid phase
20 extraction (SPE) system. In some embodiments, both the ion exchange and the desalting are performed on the same automated SPE system. In other embodiments, the ion exchange is performed on a column and the eluate is directed into the automated SPE system.

In some embodiments, if proteins are present in small amounts, samples can be
25 loaded onto the SPE columns multiple times in order to obtain a sufficient amount for analysis. Thus, the present invention has the added advantage of allowing the identification of proteins with a low level of expression.

2. Automated Sample Handling

As described in the preceding section, in preferred embodiments, samples are processed using an automated sample handling system. The present invention is not limited to any one automated sample handling system. However, in some preferred
5 embodiments, an on-line automated, SPE system is utilized (*e.g.*, including, but not limited to, the Prospekt automated SPE system; Spark Holland Instrumenten, The Netherlands). The advantage of on-line SPE is the direct elution of the extract from the SPE cartridge into the second phase (*e.g.*, LC system) by the LC mobile phase. Several laborious handling steps are thus omitted, making on-line SPE much more
10 efficient and providing superior analytical results. The superior analytical performance of on-line SPE is derived from the elimination of eluate collection, evaporation, reconstitution and injection, thus eliminating several major error sources. In addition, on-line elution transfers 100% of the purified analytes from the extraction cartridge into the LC (*e.g.*, HPLC). This provides maximum precision and sensitivity, as well
15 as reduced costs, thus saving solvents, glassware, and labor time. In addition, samples and SPE cartridges are processed in a completely closed system making sample tracking easy and protecting samples against light and air. It also protects the operator from contact with hazardous samples or solvents. Furthermore, less handling means fewer failures and high pressure solvent control for SPE makes the process
20 independent of cartridge back pressure.

3. Separation in a Second Phase

In some preferred embodiments, following the first separation phase, products of the separation step are fed directly into a second liquid phase separation step. The second dimension separates proteins based on a second physical property (*i.e.*, a
25 different property than the first physical property) and is preferably conducted in the liquid phase (*e.g.*, liquid-phase size exclusion). For example, in some embodiments of the present invention, proteins are separated by hydrophobicity using non-porous reversed phase HPLC (*See e.g.*, Liang *et al.*, *Rap. Comm. Mass Spec.*, 10:1219 [1996];

Griffin *et al.*, Rap. Comm. Mass Spec., 9:1546 [1995]; Opiteck *et al.*, Anal. Biochem. 258:344 [1998]; Nilsson *et al.*, Rap. Comm. Mass Spec., 11:610 [1997]; Chen *et al.*, Rap. Comm. Mass Spec., 12:1994 [1998]; Wall *et al.*, Anal. Chem., 71:3894 [1999]; Chong *et al.*, Rap. Comm. Mass Spec., 13:1808 [1999]).

5 This method provides for exceptionally fast and reproducible high-resolution separations of proteins according to their hydrophobicity and molecular weight. The non-porous (NP) silica packing material used in these reverse phase (RP) separations eliminates problems associated with porosity and low recovery of larger proteins, as well as reducing analysis times by as much as one third.

10 In preferred embodiments, an automated on-line sample handling system utilized in the present invention fully integrates the second separation phase with the first separation step. The sample flows directly from the first phase (*e.g.*, ion exchange) through a desalting step (*e.g.*, SPE) to the second phase (*e.g.*, NP-RP HPLC). In preferred embodiments (*e.g.*, those utilizing the Prospekt system) the
15 HPLC column is integrated into the automated sample handling system. For example, a multi valve system can be utilized where valve-switching is used to bring the extraction cartridge into the HPLC system. In some embodiments, a sample is passed through the second phase separation step (*e.g.*, NP-RP HPLC) greater than one time (*e.g.*, twice) in order to improve selectivity and resolution. For example, in some
20 embodiments, two different NP-RP-HPLC columns are utilized in tandem. The automation of protein separation increases efficiency and speed as well as decreases sample loss or potential contamination that may occur through handling.

B. Protein Identification by Mass Spectroscopy

25 Following separation in the first and second phase, the automated sample handling system transfers samples to the mass spectroscopy step. The present invention is not limited to any one mass spectroscopy technique. Indeed, a variety of techniques are contemplated. For example, techniques that find use with the present invention include, but are not limited to, ion trap mass spectrometry, ion trap/time-of-

flight mass spectrometry, quadrupole and triple quadrupole mass spectrometry, Fourier Transform (ICR) mass spectrometry, and magnetic sector mass spectrometry. In preferred embodiments, the MS analysis is automated and is performed on-line. In some embodiments, the eluent from the second separation phase is split into two
5 fractions. A fraction of the effluent is used to determine molecular weight by either MALDI-TOF-MS or ESI or TOF (LCT, Micromass) (*See e.g.*, U.S. Pat. No. 6,002,127). The remainder of the eluent is used to determine the identity of the proteins via digestion of the proteins and analysis of the peptide mass map fingerprints by either MALDI-TOF-MS or ESI or TOF. The molecular weight 2-D protein map is
10 matched to the appropriate digest fingerprint by correlating the molecular weight total ion chromatograms (TIC's) with the UV-chromatograms and by calculation of the various delay times involved. The UV-chromatograms are automatically labeled with the digest fingerprint fraction number. The resulting molecular weight and digest mass fingerprint data can then be used to search for the protein identity via web-based
15 programs like MSFit (UCSF).

A detailed discussion of the use of 3-D maps generated by the automated separation process of the present invention to identify and characterize proteins is provided in the above sections. In some embodiments, the present invention provides a 3-D map in which the first dimension represents a first physical property (*e.g.*,
20 charge or isoelectric point), the second dimension represents a second physical property (*e.g.*, hydrophobicity or molecular weight), and the third dimension represents the molecular weight and relative abundance of proteins present in the sample. In some embodiments, the data from the 3-D protein map is used to search protein data bases in order to determine the identity of the proteins.

25 In some embodiments of the present invention, sample analysis is automated and integrated with the centralized control network. For example, mass spectroscopy data is transferred to an integrated computer system containing software for the generation of 3-D protein maps. The integrated computer system is also capable of searching databases and generating a report. The report is provided to the operator in
30 a format that is customized to the particular application. For example, if an

experiment was designed to identify unknown components of a solution, the report identifies components of the 3-D map as particular proteins. Conversely, if an experiment is designed to compare the protein expression profiles of two samples, the report may identify proteins that are present in one sample and absent in another or are present at different abundances between the two samples.

C. Automated Protein Separation and Characterization in Practice

Illustrative Example 8 describes one particular embodiment of the present invention where an automated on-line Prospekt system was used to separate a protein sample based on charge and hydrophobicity. Siberian Permafrost whole cell lysate was first separated using a mini MonoQ anion exchange column. A graph of the Mini Q column eluent is shown in Figure 17. Fractions (1 minute each) from the anion exchange column gradient were fed directly into the second step using the automated Prospekt system. The Prospekt then trapped the fractions on 10 C4 SPE cartridges. Each cartridge was washed with the reverse-phase HPLC starting buffer to remove residual salt. The Prospekt system integrates the HPLC and SPE steps with a multi valve switching system. Following the wash step, the eluent from the SPE cartridge was directly transferred to the NP-RP HPLC column.

The fractions were separated using a tandem column method. A gradient was applied to the HPLC column. The HPLC column was then switched back to the initial buffer and allowed to equilibrate. The eluent from the first gradient is then passed through a second (different) HPLC column. The use of a second tandem column increases resolution and selectivity. This step is repeated for each of the SPE cartridges (each representing one anion exchange fraction).

Following separation by NP-RP-HPLC, protein fractions were analyzed online by MS to determine their molecular weight and abundance. The eluent from the column was split into two fractions. One fraction is digested enzymatically before MS. Both the digested and non-digested sample were analyzed by ESI or TOF TIC (total ion count) mass spectroscopy. Total ion count profiles are shown in Figures 18A and 18B.

EXPERIMENTAL

The following examples serve to illustrate certain preferred embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof.

EXAMPLE 1

HEL Cell Sample Preparation

The human erythroleukemia (HEL) cell line was obtained from the Department of Pediatrics at The University of Michigan. HEL cells were cultured (7% CO₂, 37 °C) in RPMI-1640 medium (Gibco) containing 4 mM glutamine, 2 mM pyruvate, 10 % fetal bovine serum (Gibco), penicillin (100 units per mL), streptomycin (100 units per mL) and 250 mg of hygromycin (Sigma). The HEL cell pellets were washed in sterile PBS, and then stored at -80 °C. The cell pellets were then re-suspended in 0.1% n-octyl β-D-galactopyranoside (OG) (Sigma) and 8 M urea (Sigma) and vortexed for 2 minutes to effect cell disruption and protein solubilization. The whole cell protein extract was then diluted to 55 mL with the Rotofor buffer and introduced into the Rotofor separation chamber (Biorad).

EXAMPLE 2

1-D Gel and SDS PAGE Separation

HEL cell proteins, resolved by Rotofor separation into discrete pI ranges, were further resolved according to their apparent molecular weight by SDS-PAGE. This procedure takes approximately 14 hours to complete. Samples of rotofor fractions were suspended in an equal volume of sample buffer (125 mM Tris (pH 6.8) containing 1% SDS, 10% glycerol, 1% dithiothreitol and bromophenol blue) and boiled for 5 min. They were then loaded onto 10% acrylamide gels. The samples were electrophoresed at 40 volts until the dye front reached the opposite end of the gel. The resolved proteins were visualized by silver staining. The gels were fixed overnight in 50% ethanol containing 5% glacial acetic acid, then washed successively (for 2 hours each) in 25% ethanol containing 5% glacial acetic acid, 5% glacial acetic

acid, and 1% glacial acetic acid. The gels were impregnated with 0.2% silver nitrate for 25 min. and were developed in 3% sodium carbonate containing 0.4% formaldehyde for 10 min. Color development was terminated by impregnating the gels with 1% glacial acetic acid, after which the gels were digitized.

5

EXAMPLE 3

2-D PAGE

In order to prepare protein extracts from the HEL cells, the harvested cell pellets were lysed by addition of three volumes of solubilization buffer consisting of 8 M urea, 2% NP-40, 2% carrier ampholytes (pH 3.5 to 10), 2% β -mercaptoethanol and
10 10 mM PMSF, after which the buffer containing the cell extracts was transferred into microcentrifuge tubes and stored at -80°C until use.

Extracts of the cultured HEL cells were separated in two dimensions as previously described by Chen *et al.* (Chen *et al.*, *Rap. Comm. Mass Spec.* 13:1907 [1999]) with some modifications as described below. Subsequent to cellular lysis in
15 solubilization buffer, the cell lysates from approximately 2.5×10^6 cells were applied to isoelectric focusing gels. Isoelectric focusing was conducted using pH 3.5 to 10 carrier ampholytes (Biorad) at 700 V for 16 h, followed by 1000 V for an additional 2 hours. The first dimension tube gel was soaked in a solution of 2 mg/mL of dithioerythritol (DTE) for 10 minutes, and then soaked in a solution of 20 mg/mL of
20 iodoacetamide (Sigma) for 10 minutes, both at room temperature. The first-dimension tube gel was loaded onto a cassette containing the second dimension gel, after equilibration in second-dimension sample buffer (125 mM Tris (pH 6.8), containing 10% glycerol, 2% SDS, 1% dithioerythritol and bromophenol blue). For the second-dimension separation, an acrylamide gradient of 11.5% to 14% was used, and the
25 samples were electrophoresed until the dye front reached the opposite end of the gel. The separated proteins were transferred to an Immobilon-P PVDF membrane. Protein patterns in some gels were visualized by silver staining or by Coomassie blue staining, and on Immobilon-P membranes by Coomassie blue staining of the membranes.

EXAMPLE 4

Rotofor Isoelectric Focusing

A preparative scale Rotofor (Biorad) was used in the first dimension separation. This device separated the proteins in liquid phase according to their pI, and is capable of being loaded with up to a gram of protein, with the total buffer volume being 55 mL. Alternatively, for analysis of smaller quantities of protein, a mini-Rotofor with a reduced volume can be used. These proteins were separated by isoelectric focusing over a 5 hour period where the separation temperature was 10 °C and the separation buffer contained 0.1 % n-octyl β -D-galactopyranoside (OG) (Sigma), 8 M urea (ICN), 2 % β -mercaptoethanol (Biorad) and 2.5 % Biolyte ampholytes, pH 3.5-10 (Biorad). The procedure used for running the Rotofor (Rotofor Purification System, Biorad) was of the standard procedure described in the manual from Biorad as modified herein. The 20 fractions contained in the Rotofor were collected simultaneously, into separate vials using a vacuum source attached by plastic tubing to an array of 20 needles, which were punched through a septum. The Rotofor fractions were aliquotted into 400 μ L amounts in polypropylene microcentrifuge tubes and could be stored at -80 °C for further analysis if necessary. An advantage of gel methods is the ability to store proteins stably in gels at 4 °C for further use. The concentration of protein in each fraction was determined via the Biorad Bradford based protein assay. The pH of the fractions was determined using pH indicator paper (Type CF, Whatman).

EXAMPLE 5

NP RP HPLC

Separations were performed at a flow rate of 1.0 mL/minute on an analytical (4.6 * 14 mm) NP RP HPLC column containing 1.5 μ m C18 (ODSI) non-porous silica beads (Micra Scientific Inc.). The column was placed in a Timberline column heater and maintained at 65 °C. The separations were performed using water/acetonitrile (0.1% TFA, 0.05 % OG) gradients. The gradient profile used was as follows: 1) 0 to 25% acetonitrile (solvent B) in 2 minutes; 2) 25 to 35% B in 2 minutes; 3) 35 to 45% B in 5 minutes; 4) 45 to 65% B in 1 minute; 5) 65 to 100% B in 1 minute; 6) 100%

B in 3 minutes; 7) 100 to 5% B in 1 minute. The start point of this profile was one minute into the gradient due to a one-minute dwell time. The acetonitrile was 99.93+% HPLC grade (Sigma) and the TFA were from 1 mL sealed glass ampules (Sigma). The non-ionic detergent used was n-octyl β -D-galactopyranoside (OG) (Sigma). The HPLC instrument used was a Beckman model 127s/166. Peaks were detected by absorbance of radiation at 214 nm in a 15 μ L analytical flow cell.

Protein standards (Sigma) used as MW protein markers and for correlation of retention time, molecular weight and hydrophobicity were bovine serum albumin (66 kDa), carbonic anhydrase (29 kDa), ovalbumin (45 kDa), lysozyme (14.4 kDa), trypsin inhibitor (20 kDa) and α -lactalbumin (14.2 kDa).

EXAMPLE 6

MALDI-TOF MS of NP RP HPLC Isolated Proteins

The MALDI-TOF MS analyses were performed on a Perseptive Voyager Biospectrometry Workstation equipped with delayed extraction technology, a one-meter flight tube and a high current detector. The N_2 laser provided light at 337 nm for laser desorption and ionization. MALDI-TOF MS was used to determine masses of peptides from protein digests using a modified (described herein) version of the two layer dried droplet method of Dai *et al.* (Dai *et al.*, Anal. Chem., 71:1087 [1999]). The MALDI matrix α -cyano-4-hydroxy-cinnamic acid (α -CHCA) (Sigma Chemical Corp., St Louis, MO, USA) was prepared in a saturated solution of acetone (1% TFA). This solution was diluted 8-fold in the same acetone solution (1% TFA) and then added to the sample droplet in a 1:2 ratio (v:v). The mixed droplet was then allowed to air dry on the MALDI plate prior to introduction into the MALDI TOF instrument for molecular weight analyses.

The proteins were collected into 1.5 mL polypropylene micro-tubes containing 20 μ L of 0.8 % OG in 50 % ethanol. In preparation for enzymatic digestion the acetonitrile was removed via speedvac at 45 $^{\circ}$ C for 30 minutes. A solution of 200 mM NH_4HCO_3 (ICN) / 1mM β -mercaptoethanol was then added in a 1 to 2 ratio to the remaining solution in the tubes, resulting in a solution of 50 to 100 mM NH_4HCO_3

with a total volume of approximately 150 μL . Subsequently 0.25 μg of enzyme was added to this solution and then the mixture was vortexed and placed in a 37 $^{\circ}\text{C}$ warm room for 24 hours. The enzymes used were either trypsin (Promega, TPCK treated), which cleaves at the carboxy side of the arginine and lysine residues, or Glu-C (Promega), which in 50 - 100 mM NH_4HCO_3 solution cleaves at the carboxy side of the glutamic acid residues.

The digest solutions were typically 100 μL in volume and 30 to 50 μL of this solution was desalted and concentrated to a final volume of 5 μL using Zip-Tips (Millipore) with 2 μL C18 resin beds. The purified peptide solution was then used to spot onto the MALDI plate for subsequent MALDI-TOF MS analysis. All spectra were obtained with 128 averages and internally or externally calibrated using the PerSeptive standard peptide mixture containing angiotensin I, ACTH(1-17), ACTH(18-39) and ACTH(7-38) (PerSeptive Biosystems).

These digests were then used to aid in the identification of the proteins by MALDI-TOF MS analysis and MSFit database searching (Wall *et al.*, Anal. Chem., 71:3894 [1999]). The peptide mass maps were searched against the Swiss and NCBI protein databases using MSFit allowing for 2 missed cleavages. The molecular weight ranged from 5 kDa to 70 kDa and the pI ranged over the full pI range. Externally calibrated peptide masses were searched with 400 ppm mass accuracy and internally calibrated peptide masses were searched with 200 ppm mass accuracy.

EXAMPLE 7

Chromatofocusing

In one exemplary embodiment of the chromatic focusing techniques of the present invention, proteins are extracted from cells using chemical lysing procedure. The lysis buffer consists of 6M guanidine-hydrochloride, 20 mM n-octyl β -D-glucopyranoside and 50 mM Tris. Cells are vortexed rigorously and kept overnight at - 20 $^{\circ}\text{C}$. They are subsequently centrifuged at 17,000 rpm for 20 min. The supernatant is removed from the cell debris and re-centrifuged at high speed to further remove any particulate. For the best reproducible results, lysate is best used within 48

hrs. Buffers for this CF are (A) Imidazole-HAC, 0.1% guanidine-hydrochloride, 0.05% n-octyl β -D-glucopyranoside, pH 7.2, and (B) Polybuffer 74 (diluted 1:10), 0.1% guanidine-hydrochloride, 0.05% n-octyl β -D-glucopyranoside, pH 4. The CF column in this example is Mono P HR 5/20 (Amersham Pharmacia, Uppsala, Sweden) with a flowrate of 1 mL/min at room temperature. Prior to injection lysate is equilibrated with buffer A with a loading time of 20 min. The sample loadability for this CF column is 10 mg of protein. The separation profile is monitored at 280 nm while the pH gradient is monitored using a pH flowcell meter, also from Amersham Pharmacia.

The CF column is equilibrated with buffer A to define the upper pH range (7 in this case) of the pH gradient. The second "focusing" buffer B is then applied to elute bound proteins, in the order of their isoelectric (*pI*) points. The pH of buffer B is 4, which defines the lower limit of the pH gradient. The pH gradient is formed as the eluting buffer B titrates the buffering groups on the ion-exchanger.

The *pI*-focused liquid fractions from CF are analyzed in the second dimension using NP-RP-HPLC. Non-porous RP-HPLC columns (Eichrom Technologies, Darien, IL, USA) are used as the second orthogonal separation dimension after CF in order to obtain a 2-D protein map that is capable of competing with 2-D gel. These columns are excellent for protein separation due to their high protein recovery, speed and efficiency. To achieve optimal protein separation, the columns should be kept at a high temperature (*e.g.*, 60 °C). This elevated temperature also improves selectivity. Selectivity as well as resolution can also be enhanced by using multiple NP columns in series. RP-HPLC columns packed with non-porous silica beads (Eichrom Technologies) such as ODS1, 2 and 3 are all well suited for these tasks.

Proteins that elute from NP-RP-HPLC separation can be directly analyzed by MS to determine their molecular weight, identity and relative abundance. In this case the eluted proteins are sized simultaneously by ESI-*oa*TOF MS (LCT, Micromass, Manchester, UK). The other part of the eluted proteins from the split valve can be collected using a fraction collector for enzymatic digestion to obtain peptide maps with a MALDI-TOF MS, ESI-QIT-*re*TOF MS, or ESI-*oa*TOF MS (LCT). Information

such as the molecular weight, *pI* and peptide map of a protein can then be entered into a web-based protein database program such as MS-Fit (*e.g.*, <http://prospector.ucsf.edu>) for protein identification.

Example 8

5 Automated 3-D IE NP-RP-HPLC-ESI-*oa* TOF MS

This example describes an automated system for protein separation and identification based on charge, hydrophobicity, and mass. Protein samples are separated based on charge using an ion exchange (IE) column. Protein fractions are then trapped on a solid phase extraction (SPE) column for desalting using an
10 automated Prospekt system. The Prospekt system then directs the protein fractions to a nonporous-reverse phase HPLC column (NP-RP-HPLC). The samples are then identified using ESI *oa* TOF mass spectroscopy.

A. Protein Separation and Trapping by SPE

Siberian Permafrost whole cell lysate of sample 23-9-25 (obtained from Jim
15 Tiendje, Department of Microbial Ecology, Michigan State University) was lysed using a chemical lysis procedure. The lysis buffer contained 6M guanidine-HCL, 20 mM *n*-octyl β -D-glucopyranoside and 50 mM Tris. The cells were vortexed vigorously and stored overnight at 0°C. The cells were then centrifuged at 17,000 rpm for 20 minutes. The supernatant was removed from the cellular material and then mixed 1:1
20 with an equilibration buffer for IE (10 mM KH_2PO_4 , 5%MeOH, 0.1 % *n*-octyl β -D-glucopyranoside, pH 8). The sample was then injected into a Mini Q anion exchange column (Amersham Pharmacia, Uppsala, Sweden) with a flow rate of 1 ml/min at 27°C. Equilibration buffer was run through the column for 3 minutes, followed by a 0% to 100% gradient of buffer B (10 mM KH_2PO_4 , 5%MeOH, 0.1 % *n*-octyl β -D
25 glucopyranoside, 1M NaCl, pH 7) in 15 minutes. A graph of the Mini Q column eluent is shown in Figure 17.

Fractions (1 minute each) are each collected on a separate solid phase extraction (SPE) cartridge by directing the eluent from the IE through 10 C4 SPE

cartridges. A Prospekt on-line automated SPE system (Spark Holland Instrumenten, The Netherlands) was utilized for the SPE, HPLC, and MS phases.

B. Protein Purification and Separation by NP-RP-HPLC

5 The initial mobile phase buffer for the RP analysis was 5 % buffer B (0.1% TFA in ACN) in buffer A (0.1 % TFA in H₂O). This solution was directed through the SPE cartridge until all the residual salt from the anion exchange mobile phase was removed. The eluent from the SPE cartridge was next directed by the Prospekt system directly to a HPLC for the second orthogonal separation phase.

10 Non Porous-RP columns (Eichrom Technologies, Darien, IL) were used as the second separation phase. A tandem column method was employed. ODSIIE and ODSI NP RP HPLC columns (Eichrom Technologies, Darien, IL) contained 1.5 µm C18 (ODSI) non-porous silica beads. Column dimensions were 4.6 * 33 mm (ODSIIE) and 4.6 * 14 mm (ODSI). The columns were maintained at 60°C to improve selectivity. A flow rate of 0.5 mL/min at a pressure of 5000 psi was maintained. The columns were loaded, equilibrated in the initial buffer, and the gradient was started. A gradient of buffer B (0.1% TFA in ACN) was performed as follows: 5% B for 1.5 min, 5% B to 20% B in 2 min, 20% B to 35% B in 5 min, 35% B to 60% B in 15 min, 60% B to 100% B in 5 minutes. The eluent from the first HPLC column (ODSI) was directed into the second HPLC column (ODSIIE).

20 Following the gradient, the initial mobile phase buffer was run through the RP column until a stable baseline is realized. The HPLC step was repeated for each of the SPE columns (each of which contained a 1 minute fraction from the anion exchange column).

C. Protein Identification by Mass Spectroscopy

25 Following separation by NP-RP-HPLC, protein fractions were analyzed online by MS to determine their molecular weight and abundance. Samples were analyzed by ESI or TOF TIC (total ion count) mass spectroscopy. Mass spectroscopy conditions

were as follows: capillary 2900V, sample cone 45V, extraction cone 3V, RF lens 1000V, desolution temp or 350°C, and source temp of 120°C.

Results of the ESI oa TOF TIC analysis are shown in Figures 18A and B. Figure 18A shows the total ion profile of the fraction collected from 3 to 4 of the MiniQ column; figure 18B shows the total ion profile of the fraction collected from 7 to 8 minutes.

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in the art are intended to be within the scope of the following claims.

CLAIMS

We Claim:

1. A method for characterizing proteins comprising:
 - a) providing:
 - 5 i) a sample comprising a plurality of proteins;
 - ii) a first separating apparatus that separates proteins based on a first physical property;
 - iii) a second separating apparatus that separates proteins based on a second physical property; and
 - 10 iv) a mass spectrometry apparatus;
 - b) treating said sample with said first separating apparatus to produce a first separated protein sample;
 - c) treating at least a portion of said first separated protein sample with said second separating apparatus to produce a second separated protein
15 sample; and
 - d) directly feeding said second separated protein sample from said second separating apparatus to said mass spectrometry apparatus; and
 - e) mass spectrally analyzing at least a portion of said second
20 separated protein sample with said mass spectrometry apparatus to characterize protein mass.
2. The method of Claim 1, wherein said sample comprises a cell lysate.
3. The method of Claim 1, wherein said first physical property is protein charge.
4. The method of Claim 1, wherein said first separating apparatus
25 comprises an isoelectric focusing apparatus.

5. The method of Claim 1, wherein said first separating apparatus comprises a liquid phase separating apparatus.

6. The method of Claim 1, wherein said second separating apparatus comprises a reverse phase HPLC apparatus.

5 7. The method of Claim 6, wherein said reverse phase HPLC comprises non-porous reverse phase HPLC.

8. The method of Claim 1, wherein said mass spectrometry apparatus comprises an ESI or TOF mass spectrometry apparatus.

10 9. The method of Claim 1, further comprising the step of d) displaying at least said first physical property of at least a portion of said second separated protein sample.

10. The method of Claim 9, wherein said displaying comprises a schematic representation of first and second physical properties of at least a portion of said second separated protein sample.

15 11. The method of Claim 10, wherein said first and second properties comprise pI and hydrophobicity.

20 12. The method of Claim 10, wherein said schematic representation comprises a 2-dimensional protein map, wherein said first physical property is represented on a first axis and wherein said second physical property is represented on a second axis.

13. The method of Claim 10, wherein said schematic representation further displays protein abundance of proteins represented in said schematic representation.

14. The method of Claim 13, wherein proteins are represented as bands in said schematic representation.

15. The method of Claim 14, wherein protein abundance correlates to intensity of said bands.

5 16. The method of Claim 14, wherein said schematic representation has a resolution that allows the differentiation of a first band representing a first protein and a second band representing a phosphorylated version of said first protein.

10 17. The method of Claim 1, wherein said sample comprising a plurality of proteins further comprises a buffer, wherein said plurality of proteins are solubilized in said buffer and wherein said buffer is compatible with said first and said second separating apparatus.

18. The method of Claim 17, wherein said buffer is further compatible with said mass spectrometry apparatus.

15 19. The method of Claim 17, wherein said buffer comprises a compound of the formula n-octyl C₆-C₁₂ glycopyranoside.

20. The method of Claim 19, wherein said compound of the formula n-octyl C₆-C₁₂ glycopyranoside is selected from n-octyl β-D-glucopyranoside and n-octyl β-D-galactopyranoside.

20 21. A system comprising:
a) a first separating apparatus that separates proteins based on a first physical property; and
b) a non-porous reverse phase HPLC apparatus directly connected to a mass spectrometry apparatus, wherein proteins separated by said non-

porous reverse phase HPLC apparatus are directly fed to said mass spectrometry apparatus without intervening processing.

22. The system of Claim 21, wherein said first separating apparatus comprises a liquid phase separating apparatus.

5 22. The system of Claim 22, wherein said liquid phase first separating apparatus comprises an isoelectric focusing apparatus.

23. The system of Claim 21, wherein said mass spectrometry apparatus comprises an ESI or TOF mass spectrometry apparatus.

10 24. The system of Claim 21, further comprising a detector that detects proteins separated by said second separating apparatus.

25. The system of Claim 24, further comprising a processor configured to run protein display software, wherein said protein display software produces a data representation of detected proteins.

15 26. The system of Claim 25, further comprising a display that displays said data representation, wherein said first physical property, said second physical properties, and protein abundance of at least a portion of said plurality of proteins are represented.

27. The system of Claim 26, wherein said first and second properties comprise pI and hydrophobicity.

20 28. The system of Claim 26, wherein said data representation comprises a 2-dimensional protein map, wherein said first physical property is represented on a first axis and wherein said second physical property is represented on a second axis.

29. The system of Claim 26, wherein proteins are represented as bands in said data representation.

30. The system of Claim 29, wherein protein abundance correlates to intensity of said bands.

5 31. The system of Claim 29, wherein said data representation has a resolution that allows the differentiation of a first band representing a first protein and a second band representing a phosphorylated version of said first protein.

32. A method for characterizing proteins comprising:

- 10 a) providing:
- i) a sample comprising a plurality of proteins;
 - ii) a first separating apparatus;
 - iii) a non-porous reverse phase HPLC apparatus; and
 - iv) a mass spectrometry apparatus;
- 15 b) treating said sample with said first separating apparatus to produce a first separated protein sample, wherein said first separated protein sample is collected from said first separating apparatus in a plurality of fractions, each of said fractions defined by a distinct pH range;
- 20 c) treating at least a portion of said first separated protein sample from at least one of said fractions with said non-porous reverse phase HPLC apparatus to produce a second separated protein sample; and
- d) mass spectrally analyzing at least a portion of said second separated protein sample with said mass spectrometry apparatus to characterize protein mass.

25 33. The method of Claim 32, wherein said second separated protein sample is directly fed to said mass spectrometry apparatus without an intervening protein digestion step.

34. The method of Claim 32, wherein said sample comprises a cell lysate.

35. The method of Claim 32, wherein said first separating apparatus separates proteins base on charge.

5 36. The method of Claim 35, wherein said first separating apparatus comprises an isoelectric focusing apparatus.

37. The method of Claim 32, wherein said first separating apparatus comprises a liquid phase separating apparatus.

38. The method of Claim 32, wherein said mass spectrometry apparatus comprises an ESI or TOF mass spectrometry apparatus.

10 39. The method of Claim 32, further comprising the step of e) displaying at least a first physical property of at least a portion of said second separated protein sample.

15 40. The method of Claim 39, wherein said displaying comprises a schematic representation of first and second physical properties of at least a portion of said second separated protein sample.

41. The method of Claim 40, wherein said first and second properties comprise pI and hydrophobicity.

20 42. The method of Claim 40, wherein said schematic representation comprises a 2-dimensional protein map, wherein said first physical property is represented on a first axis and wherein said second physical property is represented on a second axis.

43. The method of Claim 40, wherein said schematic representation further displays protein abundance of proteins represented in said schematic representation.

44. The method of Claim 32, wherein said sample comprising a plurality of proteins further comprises a buffer, wherein said plurality of proteins are solubilized in said buffer and wherein said buffer is compatible with said first and said second
5 separating apparatus.

45. The method of Claim 44, wherein said buffer is further compatible with said mass spectrometry apparatus.

46. The method of Claim 44, wherein said buffer comprises a compound of
10 the formula n-octyl C₆-C₁₂ glycopyranoside.

47. The method of Claim 46, wherein said compound of the formula n-octyl C₆-C₁₂ glycopyranoside is selected from n-octyl β-D-glucopyranoside and n-octyl β-D-galactopyranoside.

48. A system comprising:
15 a) a first separating apparatus;
b) a buffer that elutes protein from said first separating apparatus in a plurality of fractions, each of said fractions defined by a distinct pH range;
c) a first delivery apparatus capable of receiving separated protein in said plurality of fractions;
20 d) a non-porous reverse phase HPLC apparatus configured to receive proteins from said first delivery apparatus; and
e) a mass spectrometry apparatus configured to receive proteins from said non-porous reverse phase HPLC apparatus.

49. The system of Claim 48, wherein said mass spectrometry apparatus is configured to directly receive proteins from said non-porous reverse phase HPLC apparatus.

50. The system of Claim 48, wherein said first separating apparatus
5 comprises a liquid phase separating apparatus.

51. The system of Claim 50, wherein said liquid phase first separating apparatus comprises an isoelectric focusing apparatus.

52. The system of Claim 48, wherein said mass spectrometry apparatus comprises an ESI or TOF mass spectrometry apparatus.

53. The system of Claim 48, further comprising a detector that detects
10 proteins separated by said non-porous reverse phase HPLC apparatus.

54. The system of Claim 53, further comprising a processor configured to run protein display software, wherein said protein display software produces a data representation of detected proteins.

55. The system of Claim 54, further comprising a display that displays said
15 data representation, wherein a first physical property, a second physical properties, and protein abundance of at least a portion of said plurality of proteins are represented.

56. The system of Claim 55, wherein said first and second properties comprise pI and hydrophobicity.

57. The system of Claim 55, wherein said data representation comprises a
20 2-dimensional protein map, wherein said first physical property is represented on a first axis and wherein said second physical property is represented on a second axis.

58. An automated protein characterization system comprising:
- a) a first separating apparatus;
 - b) an automated sample handling device;
 - c) a second separating apparatus operably linked to said first separating apparatus and said sample handling device, wherein said second separating apparatus is configured to receive proteins from said first separating apparatus;
 - d) a mass spectrometry apparatus operably linked to said second separating apparatus and said sample handling device; wherein said mass spectroscopy apparatus is configured to receive proteins from said second separating apparatus; and
 - e) a processor that controls said sample handling device, said first separating apparatus, said second separating apparatus; and said mass spectrometry apparatus.
59. The system of Claim 58, wherein said processor comprises computer memory and a computer processor.
60. The system of Claim 58, wherein said processor is configured to produce a data representation of separated proteins analyzed by said mass spectrometry apparatus.
61. The system of Claim 58, wherein said automated sample handling device comprises a switchable, multi-channel valve.
62. The system of Claim 60, further comprising a display that displays said data representation.
63. The system of Claim 60, wherein said data representation comprises a first dimension representing protein charge.

64. The system of Claim 63, wherein said representation further comprises a second dimension representing protein molecular weight.

65. The system of Claim 65, wherein said data representation further represents protein abundance.

5 66. The system of Claim 58, wherein said first separating apparatus comprises a liquid phase separating apparatus.

67. The system of Claim 66, wherein said liquid phase first separating apparatus comprises an isoelectric focusing apparatus.

10 68. The system of Claim 58, wherein said second separating apparatus comprises a non-porous reverse phase HPLC apparatus.

69. The system of Claim 58, wherein said mass spectrometry apparatus comprises an ESI or TOF mass spectrometry apparatus.

15 70. The system of Claim 68, wherein said mass spectrometry apparatus is configured to directly receive proteins from said non-porous reverse phase HPLC apparatus.

71. The system of Claim 58, further comprising a solid phase extraction apparatus configured to treat proteins separated by said first separating apparatus prior to delivery of proteins to said second separating apparatus.

20 72. An automated method for separating proteins comprising:
a) providing:
i) a sample comprising a plurality of proteins,

- ii) a first separating apparatus that separates proteins based on a first physical property;
- iii) a second separating apparatus that separates proteins based on a second physical property;
- 5 iv) a mass spectroscopy apparatus; and
- v) an automated sample handling device comprising a switchable, multi-channel valve;
- b) treating said sample with said first separating apparatus to produce a first separated protein sample, wherein said first separated protein sample is collected from said first separating apparatus in a plurality of
- 10 fractions, each of said fractions defined by a distinct range of said first physical property;
- c) transferring said first separated protein sample to said second separating apparatus using said automated sample handling device;
- 15 d) treating said first separated protein sample with said second separating apparatus to produce a second separated protein sample;
- e) transferring said second separated protein sample to said mass spectroscopy apparatus using said automated sample handling device; and
- f) mass spectrally analyzing said second separated protein sample
- 20 with said mass spectroscopy apparatus to characterize protein mass.

73. The method of Claim 72, further comprising a centralized control network operably linked to said automated sample handling device, said first separating apparatus, said second separating apparatus, and said mass spectroscopy apparatus, wherein said centralized control network is configured to control said

25 automated sample handling device, said first separating apparatus, said second separating apparatus, and said mass spectroscopy apparatus.

74. The method of Claim 72, further comprising providing a solid phase extraction apparatus, wherein prior to treating said first separated sample with said

second apparatus; said first separated sample is treated with said solid phase extraction apparatus.

75. The method of Claim 72, wherein said sample comprises a cell lysate.

5 76. The method of Claim 72, wherein said first physical property is protein charge.

77. The method of Claim 72, wherein said first separating apparatus comprises an isoelectric focusing apparatus.

78. The method of Claim 72, wherein said first separating apparatus comprises a liquid phase separating apparatus.

10 79. The method of Claim 72, wherein said second separating apparatus comprises a reverse phase HPLC apparatus.

80. The method of Claim 79, wherein said reverse phase HPLC comprises non-porous reverse phase HPLC.

15 81. The method of Claim 72, wherein said mass spectrometry apparatus comprises an ESI or TOF mass spectrometry apparatus.

82. The method of Claim 72, further comprising the step of g) displaying at least said first physical property of at least a portion of said second separated protein sample.

20 83. The method of Claim 82, wherein said displaying comprises a schematic representation of first and second physical properties of at least a portion of said second separated protein sample.

84. The method of Claim 83, wherein said first and second properties comprise pI and hydrophobicity.

85. The method of Claim 83, wherein said schematic representation comprises a 2-dimensional protein map, wherein said first physical property is represented on a first axis and wherein said second physical property is represented on a second axis.

86. The method of Claim 83, wherein said schematic representation further displays protein abundance of proteins represented in said schematic representation.


87. The method of Claim 72, wherein said sample comprising a plurality of proteins further comprises a buffer, wherein said plurality of proteins are solubilized in said buffer and wherein said buffer is compatible with said first and said second separating apparatus.

88. The method of Claim 87, wherein said buffer is further compatible with said mass spectrometry apparatus.

89. The method of Claim 87, wherein said buffer comprises a compound of the formula n-octyl C₆-C₁₂ glycopyranoside.

90. The method of Claim 89, wherein said compound of the formula n-octyl C₆-C₁₂ glycopyranoside is selected from n-octyl β-D-glucopyranoside and n-octyl β-D-galactopyranoside.

FIGURE 1



• 1 = Ovalbumin (45 kDa), 2 = Carbonic Anhydrase (29 kDa), 3 = BSA (67 kDa),

FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6




FIGURE 7





FIGURE 8A



ALPHA-ENOLASE, 21/35 match
60% sequence covered
Collected from IEF-RP HPLC

FIGURE 8B





FIGURE 9



Key: the X marks the database coordinates of a given protein

FIGURE 10




FIGURE 11





FIGURE 12




FIGURE 13




FIGURE 14






FIGURE 15


A Fraction 1 (pH 6.75 – 6.55)



B Fraction 2 (pH 5.50 – 5.25)



C Fraction 3 (pH 5.20 – 4.90)



17/19

FIGURE 16




Figure 17






Figure 18

(a) Fraction collected from 3 to 4 minutes



(b) Fraction collected from 7 to 8 minutes



(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 August 2001 (16.08.2001)


PCT

(10) International Publication Number
WO 01/058925 A3

- (51) International Patent Classification⁷: C07K 1/00, B01D 15/08, G01N 30/88
- (21) International Application Number: PCT/US01/03917
- (22) International Filing Date: 7 February 2001 (07.02.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/180,911 8 February 2000 (08.02.2000) US
60/239,325 10 October 2000 (10.10.2000) US
60/239,326 10 October 2000 (10.10.2000) US
60/259,448 3 January 2001 (03.01.2001) US
- (71) Applicant (for all designated States except US): **THE REGENTS OF THE UNIVERSITY OF MICHIGAN** [US/US]; 3003 South State Street, Ann Arbor, MI 48109-1280 (US).
- (72) Inventors; and
(75) Inventors/Applicants (for US only): **LUBMAN, David, M.** [US/US]; 2012 Shadford Road, Ann Arbor, MI (US). **BARDER, Timothy, J.** [US/US]; 8205 South Cass Ave., Suite 111, Darien, IL 60561 (US). **WALL, Daniel, B.** [US/US]; 1508 Gilbert Ct., #B16, Ann Arbor, MI (US). **PARUS, Stephen, J.** [US/US]; 2234 Placid Way, Ann Arbor, MI 48105 (US). **KACHMAN, Maureen, T.** [US/US]; 2230 Parkwood Avenue, Ann Arbor, MI 48104 (US). **CHONG, Bathsheba, E.** [MY/US]; 822 South Main #2, Ann Arbor, MI (US). **NORTH, Robert** [US/US]; 3452 Richards Street, Ann Arbor, MI (US). **HORVATH, Thomas** [US/US]; 2013 Huron Parkway, Ann Arbor, MI

[Continued on next page]

(54) Title: PROTEIN SEPARATION AND DISPLAY



(57) Abstract: The present invention relates to multi-phase protein separation methods capable of resolving and characterizing large numbers of cellular proteins, including methods for efficiently facilitating the transfer of protein samples between separation phases. In particular, the present invention provides an automated system for the separation, identification, and characterization of protein samples. The present invention thus provides improved methods for the analysis of samples containing large numbers of proteins.

WO 01/058925 A3



(US). YAN, Fang [CN/US]; 4532 Chemistry Building,
Ann Arbor, MI 48105 (US).

(74) Agents: CASIMIR, David, A. et al.; Medlen & Carroll,
LLP, 101 Howard Street, Suite 350, San Francisco, CA
94105 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, MZ, NO,
NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,
TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

(88) Date of publication of the international search report:
4 September 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 01/03917

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K1/00 B01D15/08 G01N30/88

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, COMPENDEX

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>REGNIER F ET AL: "Future potential of targeted component analysis by multidimensional liquid chromatography-mass spectrometry" JOURNAL OF CHROMATOGRAPHY A, ELSEVIER SCIENCE, NL, vol. 750, no. 1-2, 25 October 1996 (1996-10-25), pages 3-10, XP004069734 ISSN: 0021-9673 page 6, paragraph 2 -page 8, column 1, paragraph 1 page 5, paragraph 2</p> <p style="text-align: center;">--- -/--</p>	1,5,6



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

21 March 2003

Date of mailing of the international search report

14.04.03

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Zinngrebe, U

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/03917

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>OPITECK G J ET AL: "TWO-DIMENSIONAL SEC/RPLC COUPLED TO MASS SPECTROMETRY FOR THE ANALYSIS OF PEPTIDES" ANALYTICAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, COLUMBUS, US, vol. 69, no. 13, 1 July 1997 (1997-07-01), pages 2283-2291, XP000696556 ISSN: 0003-2700 abstract; figure 1</p>	1,2
A	<p>CHONG B E ET AL: "RAPID SCREENING OF PROTEIN PROFILES OF HUMAN BREAST CANCER CELL LINES USING NON-POROUS REVERSED-PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY SEPARATION WITH MATRIX-ASSISTED LASER DESORPTION/IONIZATION TIME-OF-FLIGHT MASS SPECTRAL ANALYSIS" RAPID COMMUNICATIONS IN MASS SPECTROMETRY, LONDON, GB, vol. 13, no. 18, 1999, pages 1808-1812, XP001006015 abstract</p>	1,2,7, 21-57
A	<p>CHONG BATHSHEBA E ET AL: "Rapid profiling of E. coli proteins up to 500 kDa from whole cell lysates using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry." RAPID COMMUNICATIONS IN MASS SPECTROMETRY, vol. 11, no. 17, 1997, pages 1900-1908, XP001039850 ISSN: 0951-4198 abstract</p>	1,2
A	<p>DAVIDSSON P ET AL: "Peptide mapping of proteins in cerebrospinal fluid utilizing a rapid preparative two-dimensional electrophoretic procedure and matrix-assisted laser desorption/ionization mass spectrometry" BBA - GENERAL SUBJECTS, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 1473, no. 2-3, 27 December 1999 (1999-12-27), pages 391-399, XP004276528 ISSN: 0304-4165 abstract page 392, column 2, paragraphs 3,4 page 394</p>	3,4, 17-20

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/03917

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>NIMURA N ET AL: "FAST PROTEIN SEPARATION BY REVERSED-PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY ON OCTADECYLSILYL-BONDED NON-POROUS SILICA GEL EFFECT OF PARTICLE SIZE OF COLUMN PACKING ON COLUMN EFFICIENCY"</p> <p>JOURNAL OF CHROMATOGRAPHY, vol. 585, no. 2, 1991, pages 207-211, XP002233957 ISSN: 0021-9673 abstract</p> <p>---</p>	7,21-57
A	<p>LEE W-C: "Protein separation using non-porous sorbents"</p> <p>JOURNAL OF CHROMATOGRAPHY B: BIOMEDICAL SCIENCES & APPLICATIONS, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 699, no. 1-2, 10 October 1997 (1997-10-10), pages 29-45, XP004094987 ISSN: 0378-4347 abstract</p> <p>---</p>	7,21-57
A	<p>MEDZIHRADSKY K F ET AL: "Protein sequence and structural studies employing matrix-assisted laser desorption ionization-high energy collision-induced dissociation"</p> <p>INTERNATIONAL JOURNAL OF MASS SPECTROMETRY AND ION PROCESSES, ELSEVIER SCIENTIFIC PUBLISHING CO. AMSTERDAM, NL, vol. 160, no. 1, 1997, pages 357-369, XP004058842 ISSN: 0168-1176 page 360 -page 361</p> <p>---</p>	8
A	<p>ANDREWS C L ET AL: "Analysis of DNA adducts using high-performance separation techniques coupled to electrospray ionization mass spectrometry"</p> <p>JOURNAL OF CHROMATOGRAPHY A, ELSEVIER SCIENCE, NL, vol. 856, no. 1-2, 24 September 1999 (1999-09-24), pages 515-526, XP004180093 ISSN: 0021-9673 page 519, column 2, paragraph 3</p> <p>---</p>	8
A	<p>WO 98 40395 A (TAYLOR PAUL D ;GJERDE DOUGLAS T (US); TRANSGENOMIC INC (US)) 17 September 1998 (1998-09-17) abstract; figure 1</p> <p>---</p> <p>-/--</p>	9-16

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/03917

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WILKINS M R ET AL: "FROM PROTEINS TO PROTEOMES: LARGE SCALE PROTEIN IDENTIFICATION BY TWO-DIMENSIONAL ELECTROPHORESIS AND AMINO ACID ANALYSIS" NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 14, January 1996 (1996-01), pages 61-65, XP002923558 ISSN: 1087-0156 abstract</p> <p>---</p>	9-16
A	<p>BINZ P A ET AL: "MOLECULAR SCANNER TO AUTOMATE PROTEOMIC RESEARCH AND TO DISPLAY PROTEOME IMAGES" ANALYTICAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, COLUMBUS, US, vol. 71, no. 21, 1 November 1999 (1999-11-01), pages 4981-4988, XP002923560 ISSN: 0003-2700 abstract</p> <p>---</p>	9-16
A	<p>BALL H L ET AL: "Purification of synthetic peptides with the aid of reversible chromatographic probes" JOURNAL OF CHROMATOGRAPHY A, ELSEVIER SCIENCE, NL, vol. 686, no. 1, 25 November 1994 (1994-11-25), pages 73-83, XP004023391 ISSN: 0021-9673 page 76, column 2, paragraph 2</p> <p>---</p>	32-57, 72-90
A	<p>WO 97 01755 A (PERSEPTIVE BIOSYSTEMS INC) 16 January 1997 (1997-01-16) page 43, line 20 -page 45, line 5; figures 3,4</p> <p>---</p>	58,72
A	<p>US 5 670 054 A (KIBBEY CHRISTOPHER EDMUND ET AL) 23 September 1997 (1997-09-23) abstract; figure 3B</p> <p>---</p>	58,72
A	<p>RICHMOND R ET AL: "High-throughput flow injection analysis-mass spectrometry with networked delivery of colour rendered results: the characterisation of liquid chromatography fractions" JOURNAL OF CHROMATOGRAPHY A, ELSEVIER SCIENCE, NL, vol. 835, no. 1-2, 12 March 1999 (1999-03-12), pages 29-39, XP004163079 ISSN: 0021-9673 abstract</p> <p>---</p> <p style="text-align: center;">-/--</p>	58,72

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/03917

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 617 048 A (WATERS INVESTMENTS LTD) 28 September 1994 (1994-09-28) abstract	58,72
A	US 5 498 545 A (VESTAL MARVIN L) 12 March 1996 (1996-03-12) abstract	58,72

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 01/03917

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

As a result of the prior review under R. 40.2(e) PCT,
no additional fees are to be refunded.

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☒ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1,2,5,6

A method for characterising proteins from a cell lysate

2. Claims: 3,4

A method for characterising proteins using isoelectric focusing

3. Claims: 7,21-31,32-47,48-57

A method for characterising proteins using non-porous reversed phase HPLC

4. Claim : 8

A method for characterising proteins using an ESI or TOF MS detector

5. Claims: 9-16

A method for characterising proteins displaying the physical separation properties of fractions of prior separation steps with the mass spectrometrically measured protein mass

6. Claims: 17-20

A method for characterising proteins using compatible solubilising sample buffer

7. Claims: 32-47,48-57,72-90

A method for characterising proteins using fractions with distinct pH range

8. Claims: 58-71,72-90

A method for characterising proteins with MS linked to sample handling device

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/03917

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9840395	A	17-09-1998	AU 746851 B2	02-05-2002
			AU 6461098 A	29-09-1998
			EP 0984978 A1	15-03-2000
			JP 2001504235 T	27-03-2001
			US 2001008761 A1	19-07-2001
			US 2002123063 A1	05-09-2002
			WO 9840395 A1	17-09-1998
WO 9701755	A	16-01-1997	EP 0835446 A2	15-04-1998
			JP 11509314 T	17-08-1999
			US 2002150926 A1	17-10-2002
			WO 9701755 A2	16-01-1997
			US 6358692 B1	19-03-2002
US 5670054	A	23-09-1997	AU 2601597 A	29-10-1997
			WO 9738303 A1	16-10-1997
EP 0617048	A	28-09-1994	EP 0617048 A1	28-09-1994
			JP 6321984 A	22-11-1994
US 5498545	A	12-03-1996	AU 2960895 A	22-02-1996
			DE 69508585 D1	29-04-1999
			DE 69508585 T2	18-11-1999
			EP 0771470 A1	07-05-1997
			JP 3344724 B2	18-11-2002
			JP 10513546 T	22-12-1998
			US RE37485 E1	25-12-2001
			WO 9603768 A1	08-02-1996

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

This Page Blank (uspto)